

# Development of PROTACs Targeting the Moonlighting Enzyme Nicotinamide Phosphoribosyltransferase (NAMPT) for Breast Cancer Therapy

Ubalda Galli,<sup>\*,#</sup> Marianna Moro,<sup>#</sup> Federica Carolina Balestrero, Giorgia Colombo, Marco Koten, Benedetta Roncaglio, Armando A. Genazzani, Silvio Aprile, Alberto Massarotti, Giuseppe Orsomando, Tracey Piralì,<sup>\*</sup> and Ambra A. Grolla



Cite This: *J. Med. Chem.* 2026, 69, 5259–5290



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** PROTACs (proteolysis-targeting chimeras) enable selective protein degradation through the ubiquitin–proteasome system and offer opportunities to target moonlighting proteins with nonenzymatic functions. We report the design, synthesis, and biological evaluation of NAMPT-directed PROTACs derived from our previously described inhibitor MV78 (7). A modular click chemistry strategy facilitated rapid assembly of a focused library by varying linker architectures and E3 ligase recruiters, with emphasis on the impact of a triazole unit. Structure–activity relationship studies revealed that eliminating the triazole from the linker and introducing an (*S*)-methyl group on the VHL ligand markedly enhanced degradation. The optimized degrader, U42, exhibited low nanomolar antiproliferative activity, robust intracellular and extracellular NAMPT degradation, excellent metabolic stability, favorable pharmacokinetics, and sustained efficacy in mammosphere models, three-dimensional breast cancer cultures not previously explored with NAMPT degraders. These findings highlight U42 as a lead compound and provide strong rationale for advancing NAMPT-directed PROTACs as a therapeutic strategy in breast cancer.



## INTRODUCTION

Moonlighting proteins exhibit multiple functions beyond their canonical enzymatic activity, often switching roles depending on cellular conditions or localizing to different subcellular compartments to perform different tasks. Extensive research has highlighted their critical involvement in cancer development and progression, making them attractive targets for drug discovery.<sup>1</sup> Among these multifunctional enzymes, nicotinamide phosphoribosyltransferase (NAMPT) stands out as a “double-faced” protein existing in two forms: intracellular NAMPT (iNAMPT) which serves as the rate-limiting enzyme in the NAD<sup>+</sup> salvage pathway, and the extracellular one (eNAMPT), which acts as a pro-inflammatory and tumorigenic cytokine.<sup>2</sup>

Tumor cells exploit iNAMPT overexpression to sustain their elevated demand for NAD<sup>+</sup>, essential for rapid proliferation, while eNAMPT promotes cancer progression by stimulating proliferation, angiogenesis, and other oncogenic processes.<sup>3,4</sup> Additionally, iNAMPT can localize to the nucleus, particularly in tumor cells, through interaction with another moonlighting protein, GAPDH, which provides NAD<sup>+</sup> at the nuclear level to support survival under conditions of oxidative stress and DNA damage.<sup>5</sup>

Given its multifaceted role in cancer, NAMPT has long been pursued as a therapeutic target. Several small molecule inhibitors (SMIs) have been developed to block the main salvage pathway, thereby depleting NAD<sup>+</sup> and inducing apoptosis.<sup>6,7</sup> To date, five NAMPT inhibitors have advanced into clinical trials: FK866 (phase II), CHS-828 (phase I), GMX-1777, a water-soluble prodrug of CHS-828 (phase I), OT-82 (phase I) and KPT-9274 (phase I), a dual PAK4/NAMPT inhibitor. However, three of these studies were terminated or withdrawn due to dose-limiting adverse effects, primarily thrombocytopenia and cardiotoxicity<sup>8</sup> or poor efficacy. The limited success may stem from the inability of SMIs to interfere with the nonenzymatic functions of eNAMPT (Figure 1a), as well as their failure to modulate NAD<sup>+</sup> homeostasis via feedback mechanisms.<sup>9</sup>

Due to the limitations of conventional enzymatic inhibitors, alternative strategies have been explored in recent years, including combination therapy with chemotherapeutic agents


Received: July 3, 2025

Revised: January 16, 2026


Accepted: January 26, 2026

Published: February 19, 2026





**Figure 1.** NAMPT and the main strategies to target NAMPT explored so far. NAMPT = nicotinamide phosphoribosyltransferase; iNAMPT = intracellular NAMPT; eNAMPT = extracellular NAMPT; SMIs = small molecule inhibitors; Abs = monoclonal antibodies.




**Figure 2.** Structure of representative inhibitors and corresponding degraders (PROTACs and ATTEC).

(GMX1777 and temozolomide, phase III), dual inhibition, antibody-drug conjugates (ADCs) and monoclonal antibodies (Abs) (Figure 1b). In contrast to SMIs, Abs effectively neutralize eNAMPT,<sup>3,10</sup> but lack activity against iNAMPT due to their macromolecular nature and limited cellular permeability. Therefore, there is a growing need for novel approaches able to simultaneously target both the enzymatic and nonenzymatic functions of NAMPT.

Protein degraders have recently emerged as a promising technology for the chemical knockdown of multifunctional

proteins<sup>11–13</sup> (Figure 1c). Among these, proteolysis targeting chimeras (PROTACs) induce the formation of a ternary complex between a protein of interest (POI) and an E3 ligase, promoting proteasomal degradation via the ubiquitin-proteasome system (UPS).<sup>14</sup> On the other hand, autophagosome-tethering compounds (ATTECs) induce POI degradation through the autophagy-lysosomal pathway (ALP).<sup>15</sup> Preclinical data suggest that protein degraders may outperform SMIs, primarily because the depletion of iNAMPT levels also leads to a reduction in eNAMPT secretion, thereby disrupting both



**Figure 3.** Design strategy for MV78-based NAMPT-targeting PROTACs.

enzymatic and nonenzymatic functions.<sup>16</sup> Additional advantages of PROTACs over SMIs include their catalytic mode of action, which enables lower dosing and potentially reduces off-target toxicity and side effects, as well as improved target selectivity, reduced risk of mutation-driven resistance and prolonged pharmacodynamic effects.

To date, only a few PROTACs targeting NAMPT have been described (Figure 2). Sheng et al. reported von Hippel-Lindau (VHL)-recruiting PROTACs bearing the thiourea<sup>17</sup> and urea-derived<sup>18</sup> inhibitors as POI ligands [PROTAC A7 (1) and B3 (2) Figure 2]. These degraders showed efficacy in murine models of colorectal and ovarian cancer, respectively. Building on the most promising degraders of the series, the same authors reported a drug-tamer-PROTAC conjugation strategy for targeted delivery.<sup>19</sup> In the same year, a photoswitchable PROTAC was developed, enabling light-dependent regulation of NAMPT and NAD<sup>+</sup> levels and allowing optical control of antitumor activity in biological systems.<sup>20</sup> Given that NAMPT degradation under physiological conditions is mainly mediated via the lysosomal pathway, the same team reported the first NAMPT-targeting ATTEC<sup>21</sup> [A3 (3) Figure 2] by retaining the thiourea warhead and by replacing the E3 ligase recruiter with ispinesib, a ligand for LC3. Using FK866 inhibitor as the POI ligand, both cereblon (CRBN)<sup>22</sup> and VHL<sup>23</sup> recruiting PROTACs have been developed [PROTAC SIAIS630120 (4) and C5 (5) Figure 2]. Among these, the degrader LYP-8 (6) (Figure 2) discovered by Liu et al. demonstrated efficacy in a colon cancer model.<sup>16</sup> Finally, by incorporating the fluorescent compound M049-0244 as the NAMPT-binding moiety, a theranostic PROTAC was described, enabling real-time detection and tracking of NAMPT degradation in living cells.<sup>24</sup>

In this study, we report the rational design, synthesis, and screening of a new series of PROTACs based on MV78 (7), a NAMPT inhibitor previously discovered by our group.<sup>25</sup> The design strategy relied on click chemistry for modular synthesis<sup>26,27</sup> (Figure 3). A systematic SAR study was performed to explore the impact of the E3 ligase selection (CRBN vs VHL), as well as the linker length and composition, with particular emphasis on the role of the embedded triazole ring in

modulating degradation efficiency. We have also studied the pharmacokinetic properties of our lead compound as well as of its analogue featuring an additional (*S*)-methyl group at the benzylic position of the VHL ligand. Finally, we have investigated the efficacy of our most promising PROTAC in a breast cancer mammosphere model, a physiologically relevant system in which NAMPT-targeting PROTACs have not been studied to date.

## RESULTS AND DISCUSSION

### Rational Design of NAMPT-Targeting PROTACs


For the design of PROTAC series, MV78 (7) (Figure 3) was selected as NAMPT-binding ligand. This inhibitor displays potent NAMPT inhibitory activity ( $IC_{50} = 18.2$  nM), reducing cell proliferation at low nanomolar concentrations ( $IC_{50}$  in SH-SY5Y = 5.8 nM) and shows good *in vitro* metabolic stability (88% residual substrate in human liver microsomes after 60 min).

Based on the docking pose previously described,<sup>25</sup> the terminal phenyl ring of the tail group, and particularly the *meta*-position, was identified as the optimal site for linker attachment, being oriented toward a solvent-exposed cavity. Accordingly, MV78-OH (8) (Figure 3), bearing a hydroxyl group at this position, was employed as the POI ligand.

To recruit E3 ligases, we used lenalidomide (9) for CRBN and an hydroxyproline-containing ligand (10) for VHL (Figure 3). These ligands were chosen as they are the best-characterized E3 ligases in targeted protein degradation, broadly expressed, supported by well-established tool ligands, and with the strongest clinical and preclinical track records.

A range of alkane and poly(ethylene glycol) (PEG)-based linkers of varying lengths were evaluated to balance physicochemical and pharmacokinetic properties (Figure 3). Alkane linkers reduce polarity and the number of hydrogen-bond acceptors, favoring permeability and metabolic stability, whereas PEG linkers can improve aqueous solubility and, in certain cases, enhance effective permeability despite higher polarity. To account for this context-dependency, we explored

Scheme 1. Synthesis of MV78-OH (8) NAMPT Ligand



both families systematically, generating matched alkane/PEG series in line with best practices for PROTAC optimization.

In our design strategy, we initially incorporated a 1,2,3-triazole moiety within the linker to exploit the efficiency of click chemistry and the well-known robustness of the triazole ring, which is known to resist hydrolysis, oxidation, and metabolic cleavage. Triazole-based linkers are widely used in degrader libraries and have yielded active PROTACs, which supported our choice at the outset. In particular, clickable linkers bearing a triazole ring in different positions relative to the E3 ligase ligand were synthesized, as well as linkers lacking the heterocycle, to assess the influence of the triazole and its positioning on degradation efficiency (Figure 3). This approach complements previous studies that highlighted the role of the triazole moiety in modulating both *in vitro* activity<sup>28</sup> and physicochemical properties.<sup>29</sup>

Two points of attachment were investigated: an ether linkage connecting the POI ligand to the linker and a secondary amide group bridging the linker to the E3 ligase binder.

#### Chemistry of NAMPT-Targeting PROTACs and Biological Identification of the Lead Compounds


For the synthesis of the PROTACs, the NAMPT inhibitor MV78 (7) was functionalized with a phenol group at the *meta*-position of the terminal phenyl ring. The synthesis of MV78-OH (8) is outlined in Scheme 1. 7-Azidoheptanoic acid (11), obtained from azidation of 7-bromoheptanoic acid, was subjected to the copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) with 3-ethynylpyridine in the presence of

$\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  and sodium ascorbate, affording the triazole intermediate 12. The carboxylic acid was then esterified under Fisher conditions and the resulting ester 13 was reduced to alcohol 14 using lithium aluminum hydride. The hydroxyl group of 14 was converted into azide 15 via *one-pot* method with DPPA, DBU and  $\text{NaN}_3$ . The azide was subsequently reduced to the corresponding amine 16 via a Staudinger reaction.<sup>25</sup> Amine 16 was then coupled with 2-iodobenzoic acid using EDCI as a coupling agent to afford amide 17. Finally, a Suzuki coupling with 3-hydroxyphenylboronic acid afforded NAMPT ligand MV78-OH (8).

The synthetic route for CRBN-recruiting PROTACs incorporating the triazole ring within alkane and PEG linkers is depicted in Scheme 2. Terminal alkynes of varying length 18–26 and 27–30 were tosylated at the hydroxyl group to afford intermediates 31–39 and 40–43. These were then reacted with MV78-OH (8) via Williamson reaction under basic conditions to yield ethers 44–52 and 53–56, respectively. Lenalidomide (9) was coupled with 2-bromoacetyl chloride to generate the bromo derivative 57, which was subsequently converted to azide 58 via nucleophilic substitution with sodium azide. The final PROTACs were obtained through CuAAC reaction between the POI ligand-bearing alkynes 44–52 and 53–56 and the CRBN ligand-bearing azide (58) furnishing the PROTACs U1–9 and U10–13, respectively.

VHL-recruiting PROTACs incorporating the triazole within alkane and PEG linkers were prepared as outlined in Scheme 3. Ethyl 4-bromobutanoate underwent a nucleophilic substitution

Scheme 2. Synthesis of CRBN-Based NAMPT Targeting PROTACs with Triazole-Containing Alkane and PEG Linkers U1–13



with sodium azide to afford azide **59**, which was hydrolyzed under basic conditions to yield carboxylic acid **60**. This intermediate was coupled with VHL ligand (**10**) using HATU as the coupling agent, providing the azido-functionalized anchor **61**. The target PROTACs **U14–17** and **U18–21** were prepared via CuAAC by reacting azide **61** with alkyne **62**, obtained through the alkylation of MV78-OH (**8**) with propargyl bromide, and the previously described alkynes **44–46** and **53–56**, respectively.


Compounds **U1–21** were biologically evaluated in cell-based assays to assess their ability to cross the plasma membrane as well as to target NAMPT. Given the essential role of NAMPT in  $\text{NAD}^+$  biosynthesis and cell viability, we investigated the cytotoxic effects of the synthesized compounds. MCF7 human breast cancer cells were treated with 1 or 10  $\mu\text{M}$  of **U1–21** for 72 h, and cell viability was assessed using the MTT assay. NAMPT

protein levels were also examined by Western blot analysis after 18 h of treatment at 1  $\mu\text{M}$ .

As shown in **Table 1**, most compounds reduced cell viability by more than 50% at 10  $\mu\text{M}$  concentration. However, none of them significantly decreased NAMPT protein levels, indicating that their activity is likely due to enzymatic inhibition rather than targeted protein degradation (**Figure S1A**).

Based on these findings, we proceeded to synthesize VHL- and CRBN-based PROTACs featuring PEG linkers lacking the triazole ring. These compounds were prepared as outlined in **Scheme 4**. MV78-OH (**8**) was reacted via a Williamson reaction with tosylated intermediates **67–70**, obtained from the corresponding alcohols **63–66**, to yield ethers **71–74**. The *tert*-butyl ester moieties were then hydrolyzed under acid conditions to afford the corresponding carboxylic acids **75–78**. Final coupling with the VHL ligand (**10**) and lenalidomide (**9**)

Scheme 3. Synthesis of VHL-Based NAMPT Targeting PROTACs with Triazole-Containing Alkane and PEG Linkers U14–21



provided the target PROTACs **U22–25** and **U26–29**, respectively.

The final series of PROTACs recruiting VHL and CRBN and bearing alkane linkers was prepared as depicted in Scheme 5. MV78-OH (**8**) was reacted via Williamson etherification with bromo methyl esters **85–90**, which were prepared from the corresponding acids **79–84** under Fisher esterification conditions. The resulting esters **91–96** were then hydrolyzed under basic conditions and coupled with the VHL ligand (**10**) and lenalidomide (**9**) to afford the target degraders **U30–35** and **U36–41**, respectively.

Next, we evaluated compounds **U22–41** for their biological activity using the same experimental setup described above. As shown in Table 2 (and Figure S1A), among the compounds lacking a triazole group in the linker, two (**U23** and **U31**) emerged as both potent cytotoxic agents and effective NAMPT degraders. To further optimize the degradation assay conditions, we performed a time-course study using **U23**, testing exposure times from 2 to 24 h. This experiment confirmed that 18 h is the optimal time point to assess the degradation activity of our PROTACs (Figure S1B).

Furthermore, we performed dose–response experiments for **U23** and **U31**, treating cells with concentrations ranging from 30 nM to 3  $\mu$ M for 18 h (Figure 4) and measuring NAMPT degradation. These assays were conducted on MCF7 cells and on a more invasive and aggressive clone of 4T1 triple-negative breast cancer cells (4T1 clone 5).<sup>30</sup> Of note, both compounds exhibited a Hook effect at concentrations above 1  $\mu$ M.  $DC_{50}$  values, calculated by excluding the concentrations affected by the Hook effect, were 171 and 107 nM for **U23** and **U31**, respectively, in MCF7 cells (Figure 4A,B), and 500 and 350 nM for **U23** and **U31**, respectively, in 4T1 cells (Figure 4C,D). These results highlight **U31** as the most potent NAMPT degrader among the VHL-based NAMPT targeting PROTACs bearing triazole-free alkane linkers.

As expected, both **U23** and **U31** retained cytotoxic activity but with lower potency compared to the parent compound **7** ( $IC_{50}$  of  $7.0 \pm 0.02$  nM in MCF7 and of  $9.6 \pm 0.03$  nM in 4T1, Figure 4E). The  $IC_{50}$  values in MCF7 cells were  $1.03 \pm 0.06$   $\mu$ M for **U23** and  $550 \pm 0.04$  nM for **U31** (Figure 4F), while in 4T1 cells the values were  $1.5 \pm 0.94$   $\mu$ M and  $687 \pm 0.03$  nM, respectively (Figure 4F). These data further confirm that **U31** is not only the most potent NAMPT degrader, but also the most effective cytotoxic agent among the synthesized compounds.

#### Validation and Optimization of the Lead Compounds


To verify the E3-ligase-based mechanism of action of our PROTACs, we assessed **U31** in the presence or absence of the proteasome inhibitor bortezomib (300 nM), in both MCF7 and 4T1 cells. In both cell lines, proteasome inhibition prevented **U31**-mediated NAMPT degradation, thereby supporting our hypothesis (Figure 5A,B).

It has been shown that the stereoselective introduction of the (*S*)-methyl group at the benzylic position of VHL ligand **10** significantly enhances its binding affinity to the VHL-E3 ligase.<sup>31</sup> We have therefore prepared **U42**, the methylated derivative of **U31**, by coupling the carboxylic acid **98** with the (*S*)-methyl VHL ligand **103** (Scheme 6).

The  $DC_{50}$  values obtained from the dose–response curve (30 nM–1  $\mu$ M) confirmed the increase in degradation efficiency, **U42** was more potent than **U31** in degrading NAMPT. Specifically, the  $DC_{50}$  was 45 nM in MCF7 cells and 55 nM in 4T1 cells (Figure 5C,D). Consequently, **U42** also more effective in inducing cell death, with an  $IC_{50}$  of  $110 \pm 0.01$  nM in MCF7 cells and  $157 \pm 0.04$  nM in 4T1 cells (Figure 5E).

Overall, these data suggest that triazole-containing linkers compromise NAMPT degradation, as evidenced by the pronounced difference in activity between **U31/U42** and **U14**, which share the same linker length (nine atoms) but exhibit opposite degradation outcomes. In the absence of structural or biophysical insights into NAMPT PROTACs, we hypothesize that the triazole imparts excessive rigidity, thereby

**Table 1.** Drug Screening Based on: (1) Cell Viability Assessed by MTT Assay after 72 h on MCF7 Cells Treated with Compound 7 and U1–21 at the Dose of 1 and 10  $\mu\text{M}$ ; (2) Western Blot Analysis Performed after 18 h on MCF7 Cells Treated with Compound 7 and U1–21 at the Dose of 1  $\mu\text{M}$ <sup>a</sup>




Cpd	E3 ligase Ligand	Linker	Viability (%)		DC <sub>50</sub> (nM)	D <sub>max</sub> (%)
			1 $\mu\text{M}$	10 $\mu\text{M}$		
7			30.0 ± 0.8	18.3 ± 0.2	n.d.	0
U1	9		73.4 ± 6.9	19.1 ± 0.2	n.d.	0
U2	9		74.7 ± 3.9	23.2 ± 0.7	n.d.	0
U3	9		89.4 ± 2.1	69.9 ± 6.9	n.d.	0
U4	9		82.2 ± 4.5	50.8 ± 2.9	n.d.	0
U5	9		86.4 ± 1.6	74.6 ± 4.0	n.d.	0
U6	9		85.7 ± 0.3	50.2 ± 0.9	n.d.	0
U7	9		87.4 ± 2.6	92.9 ± 0.9	n.d.	0
U8	9		88.6 ± 2.7	95.3 ± 1.1	n.d.	12
U9	9		87.6 ± 2.6	88.4 ± 1.2	n.d.	0
U10	9		84.6 ± 2.8	53.6 ± 2.4	n.d.	0
U11	9		84.7 ± 2.1	59.3 ± 2.8	n.d.	0
U12	9		85.7 ± 3.2	27.4 ± 0.9	n.d.	15
U13	9		91.6 ± 2.5	81.8 ± 1.8	n.d.	35
U14	10		73.9 ± 3.3	14.3 ± 2.3	n.d.	0
U15	10		68.6 ± 3.6	14.6 ± 0.9	n.d.	0
U16	10		58.9 ± 1.7	20.8 ± 1.5	n.d.	0
U17	10		73.8 ± 2.7	15.7 ± 1.7	n.d.	0
U18	10		59.0 ± 0.7	28.2 ± 0.5	n.d.	0
U19	10		66.1 ± 3.7	27.6 ± 0.2	n.d.	0
U20	10		68.0 ± 3.6	27.3 ± 0.7	n.d.	0
U21	10		71.2 ± 1.3	27.6 ± 0.4	n.d.	0

<sup>a</sup>n.d. = not determined.

restricting ternary complex stabilization. These observations are therefore most appropriately interpreted within the empirical, trial-and-error framework that still characterizes PROTAC optimization. In this regard, we decided to investigate in depth the impact of triazole within the linker by integrating experimental evidence from cells and recombinant proteins with molecular modeling, as shown in the following sections.

First, to demonstrate that our best PROTAC worked by specifically inhibiting NAMPT, we evaluated the inhibitory activity of U42 on recombinant NAMPT using an enzymatic coupled assay. In this analysis, we also included a selection of other representative PROTACs: U2, U16, U14, U23, and U31. U2 is one of the most cytotoxic compounds at 1  $\mu\text{M}$ , contains lenalidomide, and features a triazole within a 9-atom linker, but

Scheme 4. Synthesis of VHL and CRBN-Based NAMPT Targeting PROTACs with Triazole-Lacking PEG Linkers U22–29



it does not induce NAMPT degradation. **U16** is also highly cytotoxic at  $1\ \mu\text{M}$ , contains a VHL ligand and a triazole within the linker, and does not induce degradation. **U14** is cytotoxic at  $10\ \mu\text{M}$ , contains the VHL ligand and a triazole within a 9-atom linker, does not degrade NAMPT, and serves as the structural negative control of **U31/U42**. In contrast, **U23**, **U31**, and **U42** have linkers of similar length to the previous compounds but lack a triazole and are able to recruit VHL. All these compounds showed nanomolar inhibitory potency on recombinant NAMPT (Figures S5F and S2), demonstrating that, on one hand, the cytotoxic but nondegrading compounds (**U2**, **U16**, **U14**) induce cell death through NAMPT inhibition and, on the other, that our best PROTACs effectively inhibit NAMPT.

NAMPT has a twin enzyme, the nicotinic acid phosphoribosyltransferase (NAPRT), another critical enzyme in NAD salvage pathway which is structurally and functionally related to NAMPT. Despite the fact that it has previously been demonstrated that FK866 does not inhibit NAPRT (likely due to steric clashes between the inhibitor and the enzyme tunnel region),<sup>32</sup> we verified whether **U42** could exert off-target effects on NAPRT. Therefore, we first evaluated the inhibitory activity of compounds **7** and **U42** on recombinant NAPRT using an enzymatic coupled assay. As shown by Figure S3A neither compound exhibited inhibitory activity against NAPRT, even at high concentrations. Afterward, to assess whether this selectivity


was maintained in cellular models, 4T1 and MCF7 cells were treated with **U42** and NAMPT and NAPRT protein levels were monitored via Western blot. Figure S3B shows that **U42** induced NAMPT degrades without affecting NAPRT levels in either cell line.

Translating NAMPT inhibition into the cellular context, we measured the  $\text{NAD}^+$  levels in both MCF7 and 4T1 cells after 24 and 48 h of 300 nM **U42** treatment, which were significantly reduced (Figure 5G).

Once ascertained the direct involvement of NAMPT inhibition in **U42** activity, we explored the VHL recruitment. To validate the role of VHL in mediating the binding to the E3 ligase, we generated a null version of **U42**. Since the stereochemistry of the hydroxyl group on proline is crucial for VHL binding,<sup>33</sup> the negative control **U42-NC** was synthesized using VHL ligand **104**, a (*S*)-hydroxyproline diastereoisomer of VHL ligand **103**, to prevent VHL E3 ligase recruitment (Scheme 6). As shown in Figure 6A, **U42-NC** failed to degrade NAMPT in both cell lines, as expected.

Additionally, we synthesized the ligand VHL-Ac (VHL ligand **103**-Acetylated)<sup>18</sup> to test it in a NAMPT-degradation competition assay. By treating cells with compound **7**, VHL-Ac, and **U42**, either alone or in combination, we demonstrated that only **U42** alone was capable of inducing NAMPT degradation, consistent with the formation of the ternary

Scheme 5. Synthesis of VHL and CRBN-Based NAMPT Targeting PROTACs with Triazole-Lacking Alkane Linkers U30–41



complex. On the other hand, when either the POI or the E3 ligase are saturated with an excess of ligand or inhibitor, **U42** could no longer form the ternary complex, and no degradation was observed (Figure 6B,C).


To further support our findings, we performed a cellular thermal shift assay (CETSA) to assess whether **U42** penetrates the cell membrane and effectively binds to both NAMPT and VHL. As shown in Figure 6D (MCF7 cells) and Figure 6E (4T1 cells), NAMPT exhibited increased thermal stability in **U42**-treated cells compared to the control, particularly at temperatures above  $60^\circ\text{C}$ . Similarly, VHL showed enhanced stability upon **U42** treatment at temperatures above  $54^\circ\text{C}$ . Collectively, these results indicate that **U42** is able to form a ternary complex by simultaneously engaging NAMPT and VHL, thereby

promoting target degradation via UPS. On this basis, we asked whether the presence of the triazole group in the linker of **U14** effectively confers conformational rigidity by impeding binding to VHL. To verify this, we performed CETSA on 4T1 cells treated with **U14** in parallel with **U31**, its twin molecule (Figure S4A,B). **U31**, like **U42**, stabilized both NAMPT and VHL levels. Instead, **U14** only increased NAMPT levels stability without affecting VHL, suggesting an inability of **U14** to stabilize the ternary complex.

#### Impact of NAMPT Degradation on Its Extracellular Moonlighting Localization

As mentioned above, NAMPT, besides being a cytosolic enzyme, also functions as an extracellular cytokine (eNAMPT) that binds to a receptor on the plasma membrane to exert its

**Table 2. Drug Screening Based on: (1) Cell Viability Assessed by MTT Assay after 72 h on MCF7 Cells Treated with Compound 7 and U22–41 at the Dose of 1 and 10  $\mu\text{M}$ ; (2) Western Blot Analysis Performed after 18 h on MCF7 Cells Treated with Compound 7 and U22–41 at the Dose of 1  $\mu\text{M}$ <sup>a</sup>**




Cpd	E3 ligase Ligand	Linker	Viability (%)		DC <sub>50</sub> (nM)	D <sub>max</sub> (%)
			1 $\mu\text{M}$	10 $\mu\text{M}$		
7			30.0 $\pm$ 0.8	18.3 $\pm$ 0.2	n.d.	0
U22	10		61.2 $\pm$ 2.2	15.7 $\pm$ 0.5	n.d.	0
U23	10		52.4 $\pm$ 8.0	14.5 $\pm$ 0.7	171	75
U24	10		84.2 $\pm$ 1.7	25.8 $\pm$ 0.5	n.d.	0
U25	10		90.2 $\pm$ 2.5	15.4 $\pm$ 0.1	n.d.	0
U26	9		80.7 $\pm$ 1.2	15.3 $\pm$ 0.4	n.d.	0
U27	9		78.9 $\pm$ 1.4	15.4 $\pm$ 0.3	n.d.	0
U28	9		57.8 $\pm$ 1.3	15.4 $\pm$ 0.3	n.d.	0
U29	9		98.7 $\pm$ 1.9	15.3 $\pm$ 0.3	n.d.	0
U30	10		14.2 $\pm$ 1.1	12.8 $\pm$ 0.9	n.d.	0
U31	10		12.3 $\pm$ 0.3	13.2 $\pm$ 1.2	87	60
U32	10		63.2 $\pm$ 2.6	17.7 $\pm$ 0.2	n.d.	45
U33	10		31.8 $\pm$ 2.9	11.9 $\pm$ 0.6	n.d.	0
U34	10		69.3 $\pm$ 1.2	22.4 $\pm$ 0.7	n.d.	0
U35	10		72.9 $\pm$ 9.6	38.5 $\pm$ 1.9	n.d.	35
U36	9		75.8 $\pm$ 4.5	14.3 $\pm$ 1.7	n.d.	0
U37	9		109.8 $\pm$ 8.4	20.2 $\pm$ 0.4	n.d.	15
U38	9		101.7 $\pm$ 10.6	18.7 $\pm$ 0.3	n.d.	15
U39	9		67.9 $\pm$ 3.8	10.7 $\pm$ 0.1	n.d.	0
U40	9		89.4 $\pm$ 2.0	35.8 $\pm$ 0.3	n.d.	0
U41	9		109.9 $\pm$ 6.5	20.9 $\pm$ 1.2	n.d.	35

<sup>a</sup>n.d. = not determined.

effects. We therefore evaluated whether U42 could also reduce eNAMPT levels in the medium of breast cancer cells. Surprisingly, at the same time point as iNAMPT degradation (18 h in serum-free conditions), we did not appreciate any


reduction in the extracellular form, but, on the contrary, we observed a trend of increasing eNAMPT levels under U42 treatment (Figure S5A). In a previous study, Liu et al. developed FK866-based degraders aimed at selectively disrupting the



**Figure 4.** Representative images and quantification of NAMPT degradation on MCF7 cells using a dose curve of U23 (A) and U31 (B) for 18 h. Mean  $\pm$  SEM of at least 3 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$  by unpaired parametric  $t$  test. Representative images and quantification of NAMPT degradation on 4T1 cells using a dose curve of U23 (C) and U31 (D) for 18 h. Mean  $\pm$  SEM of at least 3 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$  by unpaired parametric  $t$  test. (E) Cell viability performed at 72 h on MCF7 and 4T1 cells treated with a dose curve of 7. Mean  $\pm$  SEM of at least 3 independent experiments. (F) Cell viability performed at 72 h on MCF7 (left) and 4T1 (right) cells treated with a dose curve of U23 and U31. Mean  $\pm$  SEM of at least 3 independent experiments.

nonenzymatic functions of NAMPT. They treated ovarian and colon cancer cells for 24 h, followed by a washing step and an additional 24-h incubation in serum-free medium containing the compounds.<sup>16</sup> Based on this protocol, we treated MCF7 and 4T1 cells with U42 for 18 h, washed the cells, and continued treatment in serum-free medium for additional 24 h. Under

these conditions, in addition to degradation of iNAMPT (Figure S5B), we observed a dose-dependent degradation of eNAMPT (Figure 7A,B), with a  $DC_{50}$  of 50 nM, suggesting that a longer treatment duration is required to achieve complete depletion of the extracellular form of NAMPT. A plausible explanation is the presence of intracellular pools of pre-eNAMPT that must be




**Figure 5.** Representative image and quantification of NAMPT degradation in both MCF7 (A) and 4T1 cells (B) treated for 18 h respectively with U31 (300 nM), bortezomib (300 nM) or the combination of the two. Mean ± SEM of 3 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$  by unpaired parametric  $t$  test. Representative image and quantification of NAMPT degradation in both MCF7 (C) and 4T1 cells (D) treated with a dose curve of

Figure 5. continued

U42 for 18 h. Mean  $\pm$  SEM of 3 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  by unpaired parametric  $t$  test. (E) Cell viability performed at 72 h of MCF7 and 4T1 cells treated with a dose curve of U42. Mean  $\pm$  SEM of at least 3 independent experiments. (F) NAMPT inhibitory activity with the lead compound 7 and the most representative PROTACs: U2, U14, U16, U23, U31, U42. Data are expressed as the means of three independent experiments  $\pm$  standard deviation. (G) Intracellular NAD<sup>+</sup> levels in MCF7 (up) and 4T1 cells (down) treated for 24 and 48 h U42 (300 nM). Mean  $\pm$  SEM of 4 independent experiments. \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$  by unpaired parametric  $t$  test.

Scheme 6. Synthesis of (S)-Methyl VHL Ligand-Based PROTAC U42 and Negative Control U42-NC



depleted before a measurable reduction in the extracellular fraction occurs. Conversely, the transient increase in eNAMPT observed after only 18 h of U42 treatment (Figure S5A) may reflect a compensatory or stress-induced secretory response triggered by intracellular NAMPT depletion. In this context, the time-dependent profile of eNAMPT release would be determined by both the rate of intracellular degradation and the activation of stress-regulated export pathways. Therefore, the temporal regulation of eNAMPT secretion is likely cell type-dependent and influenced by the cellular stress state induced by iNAMPT degradation.

#### Metabolic Stability and Pharmacokinetic Profile of NAMPT Degraders


The metabolic stability of U31 and U42 were assessed *in vitro* and both compounds demonstrated excellent resistance toward plasma and liver biotransformation with residual substrate greater than 90% after 60 min in the investigated settings, ruling out any noteworthy hydrolytic or oxidative degradation (Table 3).

When incubated in liver microsomes, compound U42 showed half-life ranging from 52.5 and 55.7 min in mouse liver microsomes (MLM) and human liver microsomes (HLM), respectively.

Based on these results, an explorative *in vivo* pharmacokinetic study was performed in mice to assess the PK parameters,

following intraperitoneal administration at a dose of 20 mg/kg. The two compounds showed comparable profiles (Table 3 and Figures S6–S7), which is not surprising given their structural similarity.

Although U42 was found to be stable in microsomes, its metabolic biotransformation was further investigated by high-resolution tandem mass spectrometry analysis, with data processed through Compound Discoverer 3.3. Molecular formulas of the detected metabolites were proposed based on accurate mass measurements of their protonated, biprotonated, and sodium adduct ions (Table S1), as well as their isotopic patterns. Metabolite structures were assigned by interpreting the fragment ions observed in the positive-mode MS<sup>2</sup> spectra, as detailed in Section S112 in Supporting Information. In both mouse and human liver microsomes, U42 underwent hepatic metabolism primarily through aliphatic hydroxylation (M1–M3) and desaturation (M4) reactions occurring at the hydrocarbon chain, as well as pyridine *N*-oxidation (M5) on the MV78 moiety. Additional oxidative transformations included *O*-dealkylation (M6–M7) and *N*-dealkylation (M8–M10). Notably, no metabolic modifications were observed on the triazole group and VHL ligand portion and no amide hydrolysis products were detected (Figure 8), in agreement with the known robustness of hydroxyproline-based VHL ligands. The observed metabolic profile of U42 aligns with common trends reported for




**Figure 6.** (A) Representative image and quantification of NAMPT degradation in both MCF7 (up) and 4T1 cells (down) treated for 18 h respectively with U42 (100 nM) and U42-NC (100 nM). Mean  $\pm$  SEM of 3 independent experiments. (B, C) NAMPT-degrading competition assay in MCF7 and 4T1 cells, respectively, treated with NAMPT inhibitor 7 (1  $\mu$ M) or ligand VHL-Ac (100  $\mu$ M), followed by U42 (300 nM) or DMSO treatment for 18 h. Representative images are the results of 2 independent experiments. (D, E) NAMPT and VHL levels in MCF7 and 4T1 cells, respectively, treated with U42 (10  $\mu$ M) for 5 h by cellular thermal shift assay. Representative images are the results of 2 independent experiments.

PROTACs, with biotransformation events primarily occurring

on the linker and POI ligand regions.

### Targeted NAMPT Degradation Impairs Breast Cancer Mammosphere Viability

Finally, we evaluated the efficacy of U42 in reducing tumor progression using a model that closely recapitulates three-



**Figure 7.** Representative image and quantifications of eNAMPT degradation in both MCF7 (A) and 4T1 cells (B) treated for 18 h in complete medium and then treated again for 24 h in serum-free conditions with a dose curve of U42. Mean  $\pm$  SEM of 4 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  by unpaired parametric  $t$  test.

**Table 3.** *In Vitro* Metabolic Stability Data of U31 and U42 in Mouse and Human and *In Vivo* PK Parameters of U42 Administered in Mice

<i>In vitro</i> metabolic stability data <sup>a</sup>	U31	U42
% residue after 60 min incubation		
Phosphate buffer pH = 7.4	>99%	>99%
Mouse plasma	92%	92%
Human plasma	94%	>99%
MLM	95%	>99%
U42 <sup>b</sup>		
MLM $t_{1/2}$ (min)	52.5	HLM $t_{1/2}$ (min) 55.7
MLM $CL_{in\ vitro}$ ( $\mu\text{L min}^{-1} \text{mg}^{-1}$ )	13.2	HLM $CL_{in\ vitro}$ ( $\mu\text{L min}^{-1} \text{mg}^{-1}$ ) 12.4
<i>In vivo</i> PK data <sup>c</sup> U31 U42		
$t_{1/2}$ (h)	1.6	1.6
$T_{max}$ (h)	1.0	0.5
$C_{max}$ ( $\mu\text{g L}^{-1}$ )	217.0	178.9
AUC <sub>0-t</sub> ( $\mu\text{g L}^{-1} \text{h}^{-1}$ )	382.4	412.1
CL/F ( $\text{L h}^{-1} \text{kg}^{-1}$ )	52.3	48.5

<sup>a</sup>Incubated at the concentration of 50  $\mu\text{M}$ . <sup>b</sup>Incubated at the concentration of 5  $\mu\text{M}$ . <sup>c</sup>( $n = 2$  mice for each treatment) at a dose of 20 mg/kg (i.p.).

dimensional tumor architecture *in vivo*. Both MCF7 and 4T1 cells were plated on polyHEMA-precoated plates and treated with a dose curve of U42 for 8 days. Cells have been treated with U42 at the time of plating and no additional treatment was performed during the 8 days in culture. This three-dimensional assay enables the evaluation of a PROTAC ability to inhibit the clonogenic potential of cancer cells. As shown in Figure 9A,B, treatment with U42 at 3  $\mu\text{M}$  resulted in a reduced number and area of mammospheres in both MCF7 and 4T1 cells. Additionally, U42 effectively degraded NAMPT under mammosphere culture conditions following a single administration on day 1, further supporting the notion that NAMPT degradation impairs the tumorigenic potential of breast cancer cells (Figure 9C,D). Notably, eNAMPT levels measured in mammosphere culture medium after 8 days showed a significant decrease in 4T1 cells and a trend of decrease in MCF7 cells (Figure 9E,F). Data were obtained by calculating the ratio between eNAMPT levels from ELISA assay and the number of mammospheres in each independent experiment. These data mirror the efficiency

of U42 in degrading iNAMPT and, consequently, reducing eNAMPT levels, thereby contributing to its antitumor effect.

### Mechanistic Interpretation of the Conformational Rigidity Imparted by Triazole Linkers

The SAR data highlighted a sharp dichotomy between triazole-free and triazole-containing linkers: while U31 (and its optimized analogue U42) supported robust NAMPT degradation, closely related CuAAC-derived analogues failed to induce degradation despite retaining NAMPT inhibitory activity.


To rationalize this behavior at the structural level, we selected U31 as the active reference compound and U14 as its matched negative control, since the two PROTACs share the same overall architecture and comparable NAMPT inhibition but differ by the insertion of a triazole fragment within the linker, which correlates with loss of degradation (Figure 10).

We therefore performed a molecular modeling workflow aimed at (i) generating plausible NAMPT–PROTAC–VHL ternary complexes for both compounds and (ii) assessing, through molecular dynamics (MD) simulations, whether the triazole substitution alters linker flexibility and compromises the conformational adjustments required for stable ternary complex formation.

Initially, the docking poses of MV78 (7) were reproduced according to the previously reported protocol using FRED software.<sup>25</sup> The obtained docking results confirmed the correct placement of the pyridine ring within the NAMPT active site, stabilized through  $\pi$ – $\pi$  stacking interactions with Phe193 and Tyr18', while the biphenyl moiety occupied the same solvent-exposed cavity described for previously studied analogs.

Based on these results, the PROTAC model was built by linking the 7 headgroup to the hydroxyproline-containing ligand (10) for VHL derived from the crystallographic structure (PDB ID: 7JTO). The coordinates of the VHL tail were preserved as in the experimental complex, maintaining its binding mode in the recognition pocket. The ternary complex (Figure 11) was generated using the PROTAC-Model platform reported by the authors of PROTAC-DB,<sup>34</sup> the same procedure was used to generate the ternary complex with U14.

To explore the dynamic behavior and stability of the ternary complexes, MD simulations were performed for both U31- and U14-containing assemblies, using the software Desmond. At the beginning of the simulations, the two systems exhibited very similar overall conformations, as expected due to their close



**Figure 8.** Proposed phase I metabolite profiling of compound U42 in mouse and human liver microsomes.

structural resemblance. In both cases, the PROTAC molecules share a common architecture, differing mainly by the replacement of a linker fragment with a triazole in U14. This minor structural modification resulted in nearly identical binding arrangements in the initial docked complexes (Figure S8).

However, the MD trajectories revealed that the subsequent conformational evolution of the two systems diverged significantly over time. The U31 complex achieved a stable conformation shortly after equilibration and maintained it consistently throughout the 100 ns simulation. The RMSD profiles of both the protein backbone and the ligand remained low and stable (Figures S9–S10), indicating limited structural drift during the trajectory. Analysis of protein–ligand interaction maps confirmed the persistence of key hydrogen bonds and  $\pi$ – $\pi$  stacking interactions within the NAMPT binding site, as well as stable contacts between the VHL pocket and the PROTAC tail (Figure S11). The overall ternary assembly remained compact and well-ordered, supporting the ability of U31 to maintain an effective interface between the two proteins.


In contrast, the U14-containing complex exhibited a progressive loss of structural integrity starting around the midpoint of the simulation ( $\sim 50$  ns). This trend was evident from the increase in RMSD values (Figures S12–S13) and from contact map analysis, which showed a marked decrease in persistent interactions between the NAMPT pocket and the headgroup derived from MV78 (7) (Figure S14). Representative trajectory snapshots (Figure 12) illustrate the gradual disengagement of the NAMPT-binding moiety, leading to partial disruption of the ternary architecture.

All MD simulations were carried out in triplicate using different random seeds, consistently reproducing these trends and confirming the reliability of the observed structural divergence between the two complexes.

From a mechanistic perspective, the different behaviors of U31 and U14 likely arise from the impact of the triazole substitution within the linker region. In U14, the presence of the triazole ring reduces local flexibility and may alter the torsional dynamics required to maintain an optimal spatial arrangement between the two binding domains. This constrained geometry could hinder the fine conformational adjustments necessary to accommodate both proteins simultaneously, thereby weakening the cooperative interactions that stabilize the ternary complex. Conversely, the more flexible linker of U31 appears to allow better alignment of the binding motifs, promoting sustained protein–protein association and overall complex stability.

## CONCLUSIONS

In summary, leveraging on a potent NAMPT inhibitor previously developed by our group, we designed, synthesized, and comprehensively evaluated a novel class of NAMPT-targeting PROTACs. A systematic SAR study was conducted, varying both the E3 ligase recruiter and linker structure. Unlike prior reports of NAMPT degraders,<sup>16,18</sup> our CuAAC-derived PROTACs featuring a triazole moiety in the linker failed to induce degradation, highlighting the crucial role of linker design. Additionally, none of the lenalidomide-based compounds, regardless of triazole inclusion, showed degradation capability. Consistently, molecular modeling and MD simulations provided a mechanistic rationale for this SAR, suggesting that triazole insertion rigidifies the linker and destabilizes the NAMPT–PROTAC–VHL ternary complex, thereby impairing productive



**Figure 9.** Image representation and quantification of mammosphere area in MCF7 (A) and 4T1 (B) cells on polyHEMA-precoated plates treated with a dose curve of U42 for 8 days (one single treatment at the time of plating). Mean  $\pm$  SEM of 5 independent experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$  by unpaired parametric  $t$  test. Image representation and densitometry quantification of NAMPT degradation by Western blot analysis in MCF7 (C) and

Figure 9. continued

4T1 (D) mammospheres. Mean  $\pm$  SEM of 3 independent experiments. \* $p$  < 0.05, \*\* $p$  < 0.01 by unpaired parametric  $t$  test. eNAMPT levels measured by ELISA assay in mammosphere culture medium after 8 days in MCF7 (E) and 4T1 (F) cells plated on polyHEMA-precoated plates and treated with a dose curve of U42. Mean  $\pm$  SEM of 3 independent experiments. \* $p$  < 0.05, \*\* $p$  < 0.01 by unpaired parametric  $t$  test.




Figure 10. Chemical structure and biological activity of U31 and U14.





Figure 11. Complex structure of hNAMPT-VHL-ligands. The backbone of hNAMPT is shown as cartoon representation (yellow and cyan), the backbone of VHL is shown as cartoon (salmon). PROTAC compounds U31 (A), and U14 (B) are shown as sticks, green and orange, respectively.

degradation. Notably, triazole removal restored degradation capability and led to the identification of U31, a VHL-recruiting PROTAC with nanomolar potency in MCF7 and 4T1 breast cancer cell lines. The introduction of an (*S*)-methyl group on the VHL ligand (the “magic methyl”) yielded U42, a compound with enhanced degradation potency ( $DC_{50}$  = 45 nM in MCF7, 55 nM in 4T1), and low nanomolar antiproliferative activity. The cytotoxic activity of U42 was primarily attributed to its ability to bind NAMPT, inhibit its function, and promote its proteasomal degradation, leading to a reduction in  $NAD^+$  levels in both breast cancer cell lines. Mechanistic studies employing proteasome inhibition (bortezomib) and an inactive diastereomeric control (U42-NC) confirmed that the degradation was VHL-dependent. Moreover, we validated the formation of a ternary complex among the PROTAC, NAMPT, and VHL through NAMPT-degradation competition and CETSA assays. U42 effectively promoted degradation of both intracellular and extracellular NAMPT, although full eNAMPT depletion required prolonged treatment, as shown using a modified assay protocol. Importantly, U42 retained its activity in three-dimensional mammosphere cultures, reducing both iNAMPT and eNAMPT levels and impairing clonogenic growth—suggesting a potential to diminish tumorigenic capacity.

Pharmacokinetic studies in mice demonstrated favorable *in vivo* properties for U42, supporting its progression into preclinical development.

Most published degraders employ NAMPT inhibitors such as FK866 or related analogues, which contain functional groups including acrylamides, thioureas, or ureas. These moieties have been associated with potential liabilities: the acrylamide of FK866 is electrophilic; thioureas have been reported as teratogenic,<sup>18,35</sup> and ureas can inhibit CYP450 isoforms<sup>36</sup> and have also been suggested to carry teratogenic potential. In contrast, our degraders employ MV78, a triazolopyridine derivative as the warhead. The triazole unit is generally considered chemically and metabolically stable and shows minimal CYP450 inhibition except at very high concentrations.<sup>37</sup> Metabolic profiling of our most active PROTAC confirmed a favorable stability profile, which may be partly attributed to the intrinsic robustness of the triazole in MV78. Taken together, these comparisons suggest potential advantages of MV78-based NAMPT PROTACs over previously reported scaffolds and provide a rationale for their further exploration.

The recent phase III success of vepdegestrant—an estrogen receptor (ER)—targeting PROTAC that improved progression-free survival in  $ER^+$ /HER2<sup>-</sup> breast cancer patients harboring



**Figure 12.** Representative trajectory snapshots of the ternary complex with U31 (left) and U14 (right).

ESR1 mutations—highlights the clinical promise of PROTAC-based therapies in oncology, despite their current applicability being limited to specific patient subgroups.<sup>38</sup> In this context, the present study identifies U42 as a promising NAMPT degrader with potent cellular activity and encouraging pharmacokinetics. These results provide a strong rationale for further development of NAMPT-targeting PROTACs as a therapeutic approach in breast cancer and potentially beyond. Given that systemic NAMPT inhibition is known to cause adverse effects, our future efforts will focus on tumor-selective delivery strategies.<sup>6</sup> Specifically, we aim to develop activatable PROTACs designed to restrict NAMPT degradation to the breast cancer micro-environment.

## EXPERIMENTAL SECTION

### Chemistry

**General Methods.** All reagents and solvents were purchased from commercial sources and used without further purification. As needed, the reactions were performed in oven-dried glassware under a positive pressure of dry nitrogen. Melting points were determined in an open glass capillary with a Stuart scientific SMP3 apparatus and were uncorrected. Infrared spectra were acquired with a FT-IR Thermo-Nicolet Avatar or Bruker Alpha II spectrometer. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a JEOL ECP 300 MHz spectrometer or Bruker Avance Neo 400 MHz spectrometer. Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) referenced to the residual solvent peak. The multiplicity of each signal is designated using the following abbreviations: s (singlet), d (doublet), t (triplet), q (quadruplet), quint (quintuplet), m (multiplet), br s (broad singlet), dd (doublet of doublets). Coupling constants ( $J$ ) are reported in Hertz (Hz). High-Resolution ESI-MS spectra were acquired on a Thermo Scientific Q-Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer. The spectra were recorded by infusion into the ESI source using methanol as the solvent. Flash column chromatography was performed on silica gel (Merck Kieselgel 60, 230–400 mesh ASTM). Thin layer chromatography (TLC) was carried out on plates with a layer thickness of 0.25 mm (Merck Silica gel 60 F<sub>254</sub>); when necessary, they were developed with KMnO<sub>4</sub> reagent.

Compounds MV78 (7),<sup>25</sup> VHL ligand 10,<sup>33</sup> VHL ligand 103,<sup>39</sup> and ligand VHL-Ac (VHL ligand 103-Acetylated)<sup>18</sup> were synthesized according to the literature.

Compounds 9 (lenalidomide), 18–30 (alkyne-alcohols), 63–64 (*tert*-butyl ester functionalized polyethylene glycols), 79–84 (bromo-carboxylic acids) and 104 (the *S*-hydroxyproline diastereoisomer of VHL ligand 103) were commercially available.

Synthetic methods for the preparation of amine 16, linkers 31–43, 67–70, 85–90 and <sup>1</sup>H NMR, <sup>13</sup>C NMR data of the intermediates were reported in Section S14 in Supporting Information.

The purity of final compounds was  $\geq 95\%$  and was determined by high performance liquid chromatography coupled with ultraviolet-visible detector (LC-UV) using the instrumentation and methods reported in Section S87 in Supporting Information.

### Preparation of NAMPT Ligand

#### 3'-Hydroxy-*N*-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)-heptyl)-[1,1'-biphenyl]-2-carboxamide (8)

2-Iodobenzoic acid (0.374 g, 1.51 mmol, 1.1 equiv), EDCI (0.340 g, 1.78 mmol, 1.3 equiv), TEA (0.762 mL, 5.48 mmol, 4 equiv) and DMAP (0.0167 g, 0.137 mmol, 0.1 equiv) were added to a solution of amine 16 (0.355 g, 1.37 mmol, 1 equiv) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and the reaction mixture was stirred overnight at room temperature under nitrogen. Upon completion, the reaction was diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> ( $\times 3$ ). The combined organic layers were washed with a 2 M NaOH aqueous solution ( $\times 1$ ), brine ( $\times 1$ ), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated under vacuum. The crude was purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 as eluent. The product was triturated at 0 °C with EtOAc and subsequently filtered under vacuum. 2-Iodo-*N*-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)benzamide (17) was collected as a white solid, 83% yield. IR (KBr) 3331, 3120, 2929, 2852, 1631, 1533, 1289, 806, 709 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.99 (s, 1H), 8.56 (d,  $J = 4.9$  Hz, 1H), 8.20 (d,  $J = 8.0$  Hz, 1H), 7.86–7.83 (m, 2H), 7.37–7.33 (m, 3H), 7.11–7.05 (m, 1H), 5.79 (br s, 1H), 4.43 (t,  $J = 7.0$  Hz, 2H), 3.45 (q,  $J = 6.7$  Hz, 2H), 1.98 (quint,  $J = 7.0$  Hz, 2H), 1.66–1.61 (m, 4H), 1.42 (br s, 4H) ppm; <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  169.5, 148.9, 146.8, 144.4, 142.5, 139.5, 132.9, 130.7, 128.0 (2C), 126.8, 123.7, 120.2, 92.5, 50.4, 39.7, 30.1, 29.1, 28.4, 26.6, 26.2 ppm.

Amide 17 (1.14 g, 2.35 mmol, 1 equiv) was dissolved in 1,2-dimethoxyethane (14 mL), MeOH (8.6 mL) and H<sub>2</sub>O (2 mL) in a

Schlenk tube. Then (3-hydroxyphenyl)boronic acid (0.454 g, 3.28 mmol, 1.4 equiv), palladium tetrakis (0.407 g, 0.352 mmol, 0.15 equiv) and  $K_2CO_3$  (1.29 g, 9.39 mmol, 4 equiv) were added. Subsequently the solution was degassed by bubbling a stream of nitrogen through the solvent for 10 min. The reaction was stirred at 90 °C under nitrogen atmosphere overnight. Upon completion, the reaction was filtered under vacuum and rinsed multiple times with MeOH. The filtrate was evaporated, the solid residue was suspended in water and extracted with EtOAc ( $\times 2$ ). The combined organic layers were then washed with brine ( $\times 1$ ), dried over anhydrous  $Na_2SO_4$ , filtered and the solvent was evaporated under vacuum. The crude was purified by column chromatography using EtOAc and EtOAc/MeOH 95:5 as eluents to afford MV78-OH (**8**) as a white solid (0.901 g, 84% yield).  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  9.02 (br s, 1H), 8.51 (d,  $J = 4.2$  Hz, 1H), 8.48 (s, 1H), 8.27 (dt,  $J = 8.0/1.8$  Hz, 1H), 7.81 (t,  $J = 5.6$  Hz, 1H), 7.52–7.35 (m, 5H), 7.17 (t,  $J = 8.0$  Hz, 1H), 6.88–6.86 (m, 2H), 6.78–6.75 (m, 1H), 4.46 (t,  $J = 7.1$  Hz, 2H), 3.14 (t,  $J = 6.8$  Hz, 2H), 1.94 (t,  $J = 6.9$  Hz, 2H), 1.33–1.28 (m, 6H), 1.07–1.03 (m, 2H) ppm;  $^{13}C$  NMR (101 MHz,  $CD_3OD$ )  $\delta$  171.5, 157.1, 148.1, 145.8, 143.9, 141.7, 139.8, 136.4, 133.5, 129.7, 129.4, 129.0, 127.4, 127.3, 126.9, 124.2, 121.7, 119.6, 115.3, 114.1, 50.2, 39.3, 29.8, 28.4, 28.3, 26.2, 26.0 ppm; HRMS (ESI)  $m/z$  calcd for  $C_{27}H_{30}N_5O_2$  [ $M + H$ ] $^+$  456.23940, found 456.23889.

### Synthesis of NAMPT Targeting PROTACs U1–13

**General Procedure A for the Williamson Etherification (44–56).** Under a nitrogen atmosphere MV78-OH (**8**) (1 equiv) was dissolved in dry acetonitrile (0.06 M) and  $K_2CO_3$  (4 equiv) was added. The resulting suspension was heated to 85 °C and vigorously stirred for 15 min. Subsequently, the corresponding tosylated alkyne (**31–43**) (2 equiv) was added dropwise and the reaction mixture was heated to 85 °C for 5 h. The suspension was filtered and the solid was washed with  $CH_2Cl_2$ . The filtrate obtained was concentrated in vacuo and the crude was purified by column chromatography.

#### Synthesis of

#### 2-Azido-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)acetamide (**58**)

2-Bromoacetyl chloride (1.22 g, 7.72 mmol, 2 equiv) was added to a solution of commercial lenalidomide (**9**) (1.00 g, 3.86 mmol, 1 equiv) in THF (12 mL) and the reaction was heated to reflux for 2 h under nitrogen atmosphere. Upon completion, the solvent was evaporated under vacuum, the solid residue was suspended in EtOAc at 0 °C and then filtered under vacuum. 2-Bromo-*N*-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)acetamide (**57**) was collected as a white solid (1.37 g, 94% yield); IR (neat) 3302, 3237, 3167, 3083, 2968, 2839, 1695, 1669, 1546, 1300, 1193, 750  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $(CD_3)_2SO$ )  $\delta$  11.03 (s, 1H), 10.28 (s, 1H), 7.84 (d,  $J = 7.5$  Hz, 1H), 7.56–7.52 (m, 2H), 5.15 (dd,  $J = 13.2/5.0$  Hz, 1H), 4.41 (d,  $J = 17.5$  Hz, 1H, AB system), 4.34 (d,  $J = 17.5$  Hz, 1H, AB system), 4.11 (s, 2H), 2.92 (ddd,  $J = 17.6/13.3/4.8$  Hz, 1H), 2.64–2.60 (m, 1H), 2.35 (qd,  $J = 13.1/4.3$  Hz, 1H), 2.10–2.03 (m, 1H) ppm;  $^{13}C$  NMR (101 MHz,  $(CD_3)_2SO$ )  $\delta$  173.4, 171.5, 168.2, 165.6, 134.3, 133.5, 133.3, 129.4, 125.7, 120.2, 52.0, 46.8, 31.7, 30.2, 23.1 ppm; HRMS (ESI)  $m/z$  calcd for  $C_{15}H_{15}BrN_3O_4$  [ $M + H$ ] $^+$  380.02459, found 380.02373.

$NaN_3$  (0.45 g, 6.91 mmol, 2 equiv) was added to a solution of bromo-derivative **57** (1.30 g, 3.46 mmol, 1 equiv) in acetone (15 mL) and the reaction was heated to reflux overnight. Upon completion, the solvent was evaporated under vacuum. The solid residue was suspended in water (6 mL) and  $CH_2Cl_2$  (12 mL) and then filtered under vacuum. Azide **58** was obtained as a white solid (1.04 g, 88% yield); IR (neat) 3301, 3079, 2905, 2838, 2107, 1690, 1656, 1544, 1334, 1282, 1178, 749  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $(CD_3)_2SO$ )  $\delta$  11.03 (br s, 1H), 10.23 (br s, 1H), 7.86 (dd,  $J = 7.3/1.2$  Hz, 1H), 7.57–7.51 (m, 2H), 5.15 (dd,  $J = 13.3/5.1$  Hz, 1H), 4.45 (d,  $J = 17.6$  Hz, 1H, AB system), 4.37 (d,  $J = 17.6$  Hz, 1H, AB system), 4.14 (s, 2H), 2.92 (ddd,  $J = 17.7/13.2/4.9$  Hz, 1H), 2.64–2.60 (m, 1H), 2.38 (qd,  $J = 9.0/4.3$  Hz, 1H), 2.06–2.02 (m, 1H) ppm;  $^{13}C$  NMR (101 MHz,  $(CD_3)_2SO$ )  $\delta$  173.4, 171.5, 168.2, 167.1, 134.3, 133.4, 133.2, 129.3, 125.9, 120.0, 52.6, 52.1, 47.0, 31.7, 23.1 ppm. HRMS (ESI)  $m/z$  calcd for  $C_{15}H_{15}N_6O_4$  [ $M + H$ ] $^+$  343.11548, found 343.11457.

**General Procedure B for the Click Reaction.** Azide **58** (1.2 equiv),  $CuSO_4 \cdot 5H_2O$  (0.2 equiv) and sodium ascorbate (1 equiv) were added to a solution of the corresponding alkyne (**44–56**) (1 equiv) in a mixture of THF/ $H_2O$  1:1 (0.08 M) and the reaction was stirred overnight at 55 °C. Upon completion, the solvent was evaporated under vacuum and the reaction crude was purified by column chromatography.

3'-(2-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)ethoxy)-*N*-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U1**). The compound was prepared from **44**. The crude was purified using EtOAc/MeOH 9:1 as eluent to give a white solid; yield 44%; IR (neat): 3350, 2922, 2852, 1626, 1603, 1409, 1363, 1201, 1051, 752  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  9.02 (br s, 1H), 8.52 (br s, 1H), 8.44 (s, 1H), 8.25 (d,  $J = 8.0$  Hz, 1H), 7.97 (s, 1H), 7.76 (d,  $J = 7.9$  Hz, 1H), 7.67 (d,  $J = 7.5$  Hz, 1H), 7.54–7.38 (m, 6H), 7.26 (t,  $J = 7.8$  Hz, 1H), 7.0–6.98 (m, 2H), 6.92–6.89 (m, 1H), 5.40 (s, 2H), 5.14 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.50 (s, 2H), 4.44 (t,  $J = 7.0$  Hz, 2H), 4.30 (t,  $J = 6.4$  Hz, 2H), 3.21 (t,  $J = 6.4$  Hz, 2H), 3.11 (t,  $J = 3.1$  Hz, 2H), 2.95–2.76 (m, 2H), 2.48–2.43 (m, 1H), 2.20–2.17 (m, 1H), 1.92 (quint,  $J = 6.9$  Hz, 2H), 1.31–1.24 (m, 6H), 1.04 (quint,  $J = 7.4$  Hz, 2H) ppm;  $^{13}C$  NMR (101 MHz,  $CD_3OD$ )  $\delta$  173.2, 171.4, 170.6, 169.6, 164.8, 158.6, 148.1, 147.5, 145.9, 143.9, 141.8, 139.4, 136.6, 134.5, 133.4, 133.6 (2C), 129.7, 129.4, 129.1, 128.8, 127.3 (2C), 127.0, 126.0, 124.3, 123.7, 121.7, 121.1, 120.3; 114.9, 113.5, 66.6, 52.3, 51.8, 50.2, 47.2, 39.3, 30.9, 29.7, 28.4, 28.3, 26.2, 25.9, 25.5, 22.7 ppm; HRMS (ESI)  $m/z$  [ $M + H$ ] $^+$  calcd for  $C_{46}H_{48}N_{11}O_6$  850.37890, found 850.37789.

3'-(3-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)propoxy)-*N*-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U2**). The compound was prepared from **45**. The crude was purified using EtOAc/MeOH 9:1 as eluent to give a white solid; yield 69%; IR (neat): 3055, 2922, 2853, 1687, 1637, 1602, 1545, 1433, 12.87, 1201, 1050, 751, 698  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  9.01 (br s, 1H), 8.49 (br d, 1H), 8.44 (s, 1H), 8.23 (dt,  $J = 8.4/1.3$  Hz, 1H), 7.87 (s, 1H), 7.76 (dd,  $J = 8.0/0.8$  Hz, 1H), 7.63 (d,  $J = 6.9$  Hz, 1H), 7.50–7.43 (m, 4H), 7.39–7.35 (m, 2H), 7.23 (t,  $J = 8.2$  Hz, 1H), 6.97–6.95 (m, 2H), 6.88–6.86 (m, 1H), 5.39 (s, 2H), 5.12 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.49 (s, 2H), 4.43 (t,  $J = 7.1$  Hz, 2H), 4.04 (t,  $J = 6.2$  Hz, 2H), 3.11 (t,  $J = 6.9$  Hz, 2H), 2.87 (t,  $J = 6.3$  Hz, 2H), 2.79–2.77 (m, 1H), 2.74–2.72 (m, 1H), 2.42 (qd,  $J = 13.1/4.8$  Hz, 1H), 2.18–2.11 (m, 3H), 1.91 (quint,  $J = 7.0$  Hz, 2H), 1.30–1.23 (m, 6H), 1.04 (quint,  $J = 7.5$  Hz, 2H) ppm;  $^{13}C$  NMR (101 MHz,  $CD_3OD$ )  $\delta$  173.1, 171.4, 170.6, 169.5, 164.9, 158.9, 148.2, 147.1, 146.0, 144.0, 141.8, 139.6, 136.6, 134.7, 133.5, 132.7, 132.5, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 127.0, 126.1, 124.1, 123.8, 121.7, 120.9, 120.4, 114.8, 113.6, 66.8, 52.4, 52.0, 50.2, 47.2, 39.3, 31.0, 29.7, 28.6, 28.4, 28.3, 26.2, 25.9, 22.7, 21.6 ppm; HRMS (ESI)  $m/z$  [ $M + H$ ] $^+$  calcd for  $C_{47}H_{50}N_{11}O_6$  864.39455, found 864.39332.

3'-(4-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)butoxy)-*N*-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U3**). The compound was prepared from **46**. The crude was purified using EtOAc/MeOH 9.5:0.5 as eluent to give a white solid; yield 45%; IR (neat): 3232, 3130, 3065, 2923, 2853, 1687, 1630, 1602, 1548, 1433, 1287, 1200, 1049, 751, 699  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  9.02 (br s, 1H), 8.51 (br s, 1H), 8.48 (s, 1H), 8.26 (d,  $J = 8.0$  Hz, 1H), 7.86 (s, 1H), 7.77 (d,  $J = 7.9$  Hz, 1H), 7.64 (d,  $J = 7.4$  Hz, 1H), 7.50–7.38 (m, 6H), 7.24 (t,  $J = 8.2$  Hz, 1H), 6.97–6.95 (m, 2H), 6.84 (dd,  $J = 7.7/2.0$  Hz, 1H), 5.38 (s, 2H), 5.15 (dd,  $J = 13.3/5.1$  Hz, 1H), 4.47 (s, 2H), 4.43 (t,  $J = 7.0$  Hz, 2H), 3.99 (t,  $J = 5.8$  Hz, 2H), 3.12 (t,  $J = 6.8$  Hz, 2H), 2.94–2.73 (m, 4H), 2.41 (qd,  $J = 13.2/4.6$  Hz, 1H), 2.18–2.14 (m, 1H), 1.90–1.85 (m, 6H), 1.31–1.23 (m, 6H), 1.01–0.99 (m, 2H) ppm;  $^{13}C$  NMR (101 MHz,  $CD_3OD$ )  $\delta$  173.2, 171.6, 170.7, 169.5, 164.9, 158.9, 148.1, 147.6, 145.8, 143.9, 141.7, 139.6, 136.5, 134.4, 133.4, 132.7, 132.6, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 127.0, 125.9, 124.3, 123.8, 121.7, 120.7, 120.3, 114.5, 113.4, 67.2, 52.2, 51.8, 50.2, 47.2, 39.3, 30.9, 29.8, 28.4 (2C), 26.2, 25.9, 25.7, 24.6, 22.7 ppm; HRMS (ESI)  $m/z$  [ $M + H$ ] $^+$  calcd for  $C_{48}H_{52}N_{11}O_6$  878.41020, found 878.40988.

3'-((5-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)pentyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U4**). The compound was prepared from **47**. The crude was purified using EtOAc/MeOH 9.5:0.5 and EtOAc/MeOH 8:2 as eluents to give a white solid; yield 66%; IR (neat): 3232, 3129, 3064, 2925, 2854, 1687, 1637, 1602, 1544, 1433, 1287, 1200, 1050, 751, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.02 (br s, 1H), 8.51 (br s, 1H), 8.45 (s, 1H), 8.25 (d,  $J = 8.0$  Hz, 1H), 7.83 (s, 1H), 7.77 (d,  $J = 7.8$  Hz, 1H), 7.65 (d,  $J = 7.3$  Hz, 1H), 7.51–7.44 (m, 4H), 7.39–7.36 (m, 2H), 7.23 (t,  $J = 8.0$  Hz, 1H), 6.97–6.95 (m, 2H), 6.85 (dd,  $J = 7.6/1.8$  Hz, 1H), 5.38 (s, 2H), 5.12 (dd,  $J = 13.2/5.2$  Hz, 2H), 4.50 (s, 2H), 4.44 (t,  $J = 7.0$  Hz, 2H), 3.98 (t,  $J = 6.3$  Hz, 2H), 3.13 (t,  $J = 6.8$  Hz, 2H), 2.88–2.73 (m, 3H), 2.44 (qd,  $J = 12.6/4.9$  Hz, 1H), 2.20–2.15 (m, 1H), 1.93 (quint,  $J = 6.9$  Hz, 2H), 1.81–1.74 (m, 4H), 1.54 (quint,  $J = 7.0$  Hz, 2H), 1.30–1.27 (m, 6H), 1.08–1.03 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.1, 171.4, 170.6, 169.5, 164.9, 159.1, 148.2, 147.8, 146.0, 144.1, 141.8, 139.6, 136.6, 134.6, 133.5, 132.7, 132.6, 129.7, 129.4, 125.0, 128.8, 127.3 (2C), 127.0, 126.1, 124.1, 123.6, 121.7, 120.8, 120.4, 114.8, 113.6, 67.6, 52.4, 52.0, 50.2, 47.2, 39.3, 31.0, 29.7, 28.6 (2C), 28.4, 28.3, 26.2, 25.9, 25.3, 24.8, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{49}\text{H}_{54}\text{N}_{11}\text{O}_6$  892.42585, found 892.42511.

3'-((6-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)hexyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U5**). The compound was prepared from **48**. The crude was purified using EtOAc/MeOH 9.5:0.5 and EtOAc/MeOH 9:1 as eluents to give a white solid; yield 66%; IR (neat): 3232, 3131, 3063, 2930, 2856, 1694, 1641, 1603, 1548, 1434, 1288, 1202, 1050, 753, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.02 (br s, 1H), 8.51 (br s, 1H), 8.43 (s, 1H), 8.24 (d,  $J = 7.9$  Hz, 1H); 7.81 (s, 1H), 7.76 (d,  $J = 7.9$  Hz, 1H), 7.65 (d,  $J = 7.4$  Hz, 1H), 7.51–7.36 (m, 6H), 7.24 (t,  $J = 8.2$  Hz, 1H), 6.97–6.95 (m, 2H), 6.85 (d,  $J = 7.5$  Hz, 1H), 5.36 (s, 2H), 5.12 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.48 (s, 2H), 4.44 (t,  $J = 7.0$  Hz, 2H), 3.96 (t,  $J = 6.3$  Hz, 2H), 3.13 (t,  $J = 6.8$  Hz, 2H), 2.92–2.71 (m, 4H), 2.43 (qd,  $J = 13.1/4.7$  Hz, 1H), 2.18–2.15 (m, 1H), 1.93 (quint,  $J = 6.8$  Hz, 2H), 1.77–1.69 (m, 4H), 1.54–1.43 (m, 4H), 1.31–1.23 (m, 6H), 1.07–1.06 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.2, 171.5, 170.7, 169.5, 164.9, 159.0, 148.1, 147.9, 145.8, 144.0, 141.7, 139.6, 136.5, 134.5, 133.4, 132.7, 132.6, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 127.0, 126.0, 124.3, 123.7, 121.7, 120.7, 120.3, 114.6, 113.5, 67.6, 52.3, 51.9, 50.2, 47.1, 39.3, 30.9, 29.8, 28.9, 28.8, 28.4 (2C), 28.3, 26.2, 25.9, 25.4, 24.8, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{50}\text{H}_{56}\text{N}_{11}\text{O}_6$  906.44150, found 906.43929.

3'-((7-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)heptyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U6**). The compound was prepared from **49**. The crude was purified using EtOAc/MeOH 9.5:0.5 and EtOAc/MeOH 9:1 as eluents to give a white solid; yield 45%; IR (neat): 3233, 3130, 3055, 2928, 2854, 1689, 1627, 1602, 1547, 1433, 1286, 1202, 1051, 753, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.02 (br s, 1H), 8.50 (br s, 1H), 8.44 (s, 1H), 8.25 (dt,  $J = 8.0/1.7$  Hz, 1H), 7.81 (s, 1H), 7.77 (dd,  $J = 7.9/0.7$  Hz, 1H), 7.64 (d,  $J = 7.1$  Hz, 1H), 7.51–7.44 (m, 4H), 7.40–7.36 (m, 2H), 7.24 (t,  $J = 8.2$  Hz, 1H), 6.97–6.95 (m, 2H), 6.86–6.84 (m, 1H), 5.37 (s, 2H), 5.12 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.50 (s, 2H), 4.44 (t,  $J = 7.0$  Hz, 2H), 3.95 (t,  $J = 6.4$  Hz, 2H), 3.13 (t,  $J = 6.8$  Hz, 2H), 2.92–2.83 (m, 1H), 2.79–2.78 (m, 1H), 2.71 (t,  $J = 7.5$  Hz, 2H), 2.44 (qd,  $J = 13.0/4.8$  Hz, 1H), 2.20–2.14 (m, 1H), 1.93 (quint,  $J = 6.9$  Hz, 2H), 1.77–1.67 (m, 4H), 1.47–1.39 (m, 6H), 1.32–1.25 (m, 6H), 1.09–1.05 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.1, 171.4, 170.6, 169.5, 164.9, 159.1, 148.2, 148.0, 146.0, 144.0, 141.7, 139.6, 136.5, 134.7, 133.4, 132.7, 132.6, 129.7, 129.4, 129.0, 128.3, 127.3 (2C), 126.9, 126.1, 124.1, 123.6, 121.6, 120.7, 120.4, 114.8, 113.6, 67.8, 52.4, 51.9, 50.2, 47.2, 39.3, 31.0, 29.7, 28.9, 28.8, 28.6 (2C), 28.4, 28.3, 26.2, 25.9, 25.6, 24.9, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{51}\text{H}_{58}\text{N}_{11}\text{O}_6$  920.45715, found 920.45683.

3'-((8-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)octyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U7**). The compound was prepared from **50**. The crude was

purified using EtOAc and EtOAc/MeOH 9:1 to give a white solid; yield 64%; IR (neat): 3222, 3129, 3057, 2923, 2852, 1686, 1637, 1602, 1543, 1433, 1286, 1201, 1050, 756, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.02 (br s, 1H), 8.50 (br s, 1H), 8.46 (s, 1H), 8.25 (d,  $J = 7.2$  Hz, 1H), 7.81 (s, 1H), 7.78 (d,  $J = 7.0$  Hz, 1H), 7.64 (d,  $J = 7.5$  Hz, 1H), 7.51–7.34 (m, 6H), 7.24 (t,  $J = 8.0$  Hz, 1H), 6.97–6.92 (m, 2H), 6.86–6.84 (m, 1H), 5.38 (s, 2H), 5.13 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.50 (s, 2H), 4.45 (t,  $J = 7.1$  Hz, 2H), 3.95 (t,  $J = 6.4$  Hz, 2H), 3.13 (t,  $J = 6.9$  Hz, 2H), 2.80–2.75 (m, 1H), 2.74 (t,  $J = 7.1$  Hz, 2H), 2.50–2.39 (qd,  $J = 13.1/4.8$  Hz, 1H), 2.19–2.14 (m, 1H), 1.93 (quint,  $J = 7.0$  Hz, 2H), 1.77–1.66 (m, 4H), 1.44–1.28 (m, 14H), 1.07–1.06 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.1, 171.4, 170.6, 169.5, 165.0, 159.1, 148.2, 148.0, 146.0, 144.0, 141.7, 139.6, 136.5, 134.7, 133.4, 132.7, 132.6, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 126.9, 126.1, 124.1, 123.5, 121.6, 120.7, 120.4, 114.7, 113.6, 67.8, 52.4, 51.9, 50.2, 47.2, 39.4, 30.9, 29.7, 28.9 (2C), 28.8 (2C), 28.6, 28.4, 28.3, 26.2, 25.9, 25.7, 24.9, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{52}\text{H}_{60}\text{N}_{11}\text{O}_6$  934.47280, found 934.47196.

3'-((9-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)nonyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U8**). The compound was prepared from **51**. The crude was purified using EtOAc and EtOAc/MeOH 9:1 to give a white solid; yield 44%; IR (neat): 3232, 3131, 3056, 2924, 2852, 1689, 1636, 1602, 1545, 1433, 1286, 1201, 1050, 752, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.05 (br s, 1H), 8.53 (br s, 1H), 8.45 (s, 1H), 8.26 (d,  $J = 7.9$  Hz, 1H), 7.81 (s, 1H), 7.79 (dd,  $J = 8.0/0.6$  Hz, 1H), 7.66 (d,  $J = 7.0$  Hz, 1H), 7.52–7.36 (m, 6H), 7.24 (t,  $J = 8.2$  Hz, 1H), 6.97–6.95 (m, 2H), 6.87–6.84 (m, 1H), 5.38 (s, 2H), 5.13 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.51 (s, 2H), 4.45 (t,  $J = 7.1$  Hz, 2H), 3.85 (t,  $J = 6.4$  Hz, 2H), 3.14 (t,  $J = 6.9$  Hz, 2H), 2.93–2.84 (m, 1H), 2.80–2.74 (m, 1H), 2.70 (t,  $J = 7.5$  Hz, 2H), 2.45 (qd,  $J = 13.3/4.9$  Hz, 1H), 2.20–2.15 (m, 1H), 1.94 (quint,  $J = 6.9$  Hz, 2H), 1.73 (quint,  $J = 6.7$  Hz, 2H), 1.70–1.64 (m, 2H), 1.46–1.27 (m, 16H), 1.06 (quint,  $J = 7.3$  Hz, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.1, 171.4, 170.6, 169.5, 165.0, 159.1, 148.2, 148.0, 146.0, 144.0, 141.7, 139.6, 136.5, 134.7, 133.4, 132.7, 136.6, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 126.9, 126.1, 124.0, 123.5, 121.6, 120.7, 120.4, 114.7, 113.6, 67.8, 52.4, 51.9, 50.2, 47.2, 39.3, 31.0, 29.7, 29.0 (2C), 28.9, 28.8, 28.7, 28.4, 28.3, 26.2, 25.9, 25.7, 24.9, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{53}\text{H}_{62}\text{N}_{11}\text{O}_6$  948.48845, found 948.48849.

3'-((10-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)decyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U9**). The compound was prepared from **52**. The crude was purified using EtOAc/MeOH 9.5:0.5 and EtOAc/MeOH 8.5:1.5 to give a white solid; yield 70%; IR (neat): 3232, 3139, 3056, 2923, 2852, 1693, 1644, 1602, 1546, 1433, 1286, 1201, 1050, 752, 699  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  9.06 (br s, 1H), 8.55 (br s, 1H), 8.45 (s, 1H), 8.26 (d,  $J = 7.9$  Hz, 1H), 7.80 (s, 1H), 7.78 (dd,  $J = 8.0/0.8$  Hz, 1H), 7.65 (d,  $J = 7.5$  Hz, 1H), 7.52–7.36 (m, 6H), 7.24 (t,  $J = 8.1$  Hz, 1H), 6.97–6.95 (m, 2H), 6.87–6.84 (dt,  $J = 9.2/1.8$  Hz, 1H), 5.36 (s, 2H), 5.13 (dd,  $J = 13.2/5.2$  Hz, 1H), 4.50 (s, 2H), 4.45 (t,  $J = 7.1$  Hz, 2H), 3.96 (t,  $J = 6.4$  Hz, 2H), 3.14 (t,  $J = 6.9$  Hz, 2H), 2.89–2.79 (m, 1H), 2.78–2.74 (m, 1H), 2.70 (t,  $J = 7.5$  Hz, 2H), 2.45 (qd,  $J = 13.1/4.6$  Hz, 1H), 2.20–2.14 (m, 1H), 1.94 (quint,  $J = 7.0$  Hz, 2H), 1.77–1.64 (m, 4H), 1.45 (quint,  $J = 7.0$  Hz, 2H), 1.36–1.28 (m, 16H), 1.07 (quint,  $J = 7.4$  Hz, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  173.2, 171.5, 170.7, 169.5, 164.9, 159.0, 148.1, 148.0, 145.9, 144.0, 141.7, 139.6, 136.5, 134.6, 133.4, 132.7, 132.6, 129.7, 129.4, 129.0, 128.8, 127.3 (2C), 127.0, 126.0, 124.3, 123.6, 121.7, 120.7, 120.3, 114.6, 113.5, 67.7, 52.3, 51.9, 50.2, 47.1, 39.3, 30.9, 29.8, 29.2, 29.1, 29.0 (3C), 28.9, 28.7, 28.4, 28.3, 26.2, 25.9, 25.8, 24.9, 22.7 ppm; HRMS (ESI),  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{54}\text{H}_{64}\text{N}_{11}\text{O}_6$  962.50410, found 962.50260.

3'-((11-(1-(2-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)undecyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U10**). The compound was prepared from alkyne **53**. The crude was purified using EtOAc and EtOAc/MeOH 9:1 as eluents. White solid; yield 64%; IR (neat) 3232, 3140, 3056, 2931, 2859, 1694, 1636, 1603, 1548, 1434, 1203, 1051, 753  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,

CD<sub>3</sub>OD)  $\delta$  9.02 (s, 1H), 8.50–8.48 (m, 2H), 8.26 (dt,  $J$  = 8.0/1.9 Hz, 1H), 8.08 (s, 1H), 7.76 (d,  $J$  = 7.9 Hz, 1H), 7.63 (d,  $J$  = 7.3 Hz, 1H), 7.50–7.36 (m, 6H), 7.24 (t,  $J$  = 8.2 Hz, 1H), 6.98–6.97 (m, 2H), 6.87–6.85 (dd,  $J$  = 8.1/1.8 Hz), 5.43 (s, 2H), 5.14 (dd,  $J$  = 13.3/5.1 Hz, 1H), 4.73 (s, 2H), 4.47 (s, 2H), 4.43 (t,  $J$  = 7.0 Hz, 2H), 4.14–4.13 (m, 2H), 3.90–3.87 (m, 2H), 3.12 (t,  $J$  = 6.8 Hz, 2H), 2.93–2.84 (m, 1H), 2.77–2.71 (m, 1H), 2.46–2.36 (m, 1H), 2.17–2.12 (m, 1H), 1.89 (quint,  $J$  = 6.9 Hz, 2H), 1.28–1.22 (m, 6H), 0.98 (quint,  $J$  = 6.9 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD)  $\delta$  173.1, 171.4, 170.6, 169.4, 164.7, 158.8, 148.1, 146.0, 144.8, 144.0, 141.8, 139.5, 136.6, 134.7, 133.4, 132.7, 132.5, 129.7, 129.4, 129.0, 128.8, 127.5, 127.3, 127.0, 126.1, 125.4, 124.1, 121.6, 121.1, 120.4, 114.9, 113.7, 68.8, 67.4, 63.9, 52.4, 52.0, 50.2, 47.1, 39.3, 30.9, 29.7, 28.4, 28.2, 26.1, 25.9, 22.7 ppm; HRMS (ESI)  $m/z$  calcd for C<sub>47</sub>H<sub>50</sub>N<sub>11</sub>O<sub>7</sub> [M + H]<sup>+</sup> 880.38947, found 880.38806.

3'-(2-(2-((1-(2-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (U11). The compound was prepared from alkyne 54. The crude was purified using EtOAc and EtOAc/MeOH 9:1 as eluents. White solid; yield 64%; IR (neat): 3231, 3130, 3056, 2923, 2855, 1687, 1636, 1602, 1547, 1433, 1201, 1051, 752 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  9.03 (s, 1H), 8.49 (s, 1H), 8.47 (s, 1H), 8.28 (d,  $J$  = 8.0 Hz, 1H), 8.06 (s, 1H), 7.77 (d,  $J$  = 7.9 Hz, 1H), 7.63 (d,  $J$  = 7.5 Hz, 1H), 7.53–7.35 (m, 6H), 7.22 (t,  $J$  = 8.1 Hz, 1H), 6.98–6.96 (m, 2H), 6.86 (d,  $J$  = 7.2 Hz, 2H), 5.36 (s, 2H), 5.13 (dd,  $J$  = 12.3/5.1 Hz, 1H), 4.66 (s, 2H), 4.46–4.43 (m, 4H), 4.10 (quint,  $J$  = 4.6 Hz, 2H), 3.81 (quint,  $J$  = 4.5 Hz, 2H), 3.70 (br s, 4H), 3.13 (t,  $J$  = 6.8 Hz, 2H), 2.92–2.83 (m, 1H), 2.76–2.72 (m, 1H), 2.40–2.33 (m, 1H), 2.15–2.11 (m, 1H), 1.91 (quint,  $J$  = 6.8 Hz, 2H), 1.30–1.24 (m, 6H), 1.01 (quint,  $J$  = 7.0 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD)  $\delta$  173.1, 171.4, 170.6, 169.4, 164.7, 158.8, 148.0, 145.8, 144.8, 143.9, 141.8, 139.5, 136.5, 134.5, 133.6, 132.7, 132.6, 129.7, 129.4, 129.1, 128.8, 127.5, 127.3, 127.0, 125.9, 125.5, 124.3, 121.8, 121.0, 120.3, 114.7, 113.6, 70.4, 69.5, 69.4, 67.4, 63.7, 52.3, 31.9, 50.2, 47.0, 39.3, 30.9, 29.7, 28.4, 28.3, 26.2, 25.9, 22.7 ppm; HRMS (ESI)  $m/z$  calcd for C<sub>49</sub>H<sub>54</sub>N<sub>11</sub>O<sub>8</sub> [M + H]<sup>+</sup> 924.41568, found 924.41534.

3'-(2-(2-((1-(2-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (U12). The compound was prepared from alkyne 55. The crude was purified using EtOAc and EtOAc/MeOH 9:1 as eluents. White solid; yield 41%; IR (neat) 3218, 3129, 3049, 2920, 2856, 1686, 1637, 1602, 1543, 1432, 1201, 1051, 752 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  9.02 (s, 1H), 8.51 (s, 1H), 8.44 (s, 1H), 8.26 (d,  $J$  = 8.0 Hz, 1H), 8.03 (s, 1H), 7.76 (d,  $J$  = 8.0 Hz, 1H), 7.65 (d,  $J$  = 7.4 Hz, 1H), 7.51–7.35 (m, 6H), 7.23 (t,  $J$  = 8.0 Hz, 1H), 6.98–6.96 (m, 2H), 6.87 (d,  $J$  = 7.4 Hz, 1H), 5.36 (s, 2H), 5.12 (dd,  $J$  = 13.2/5.2 Hz, 1H), 4.66 (s, 2H), 4.47–4.43 (m, 4H), 4.13–4.10 (m, 2H), 3.82 (t,  $J$  = 4.7 Hz, 2H), 3.68–3.65 (m, 8H), 3.14 (t,  $J$  = 6.8 Hz, 2H), 2.93–2.83 (m, 1H), 2.79–2.74 (m, 1H), 2.46–2.35 (m, 1H), 2.17–2.14 (m, 1H), 1.93 (quint,  $J$  = 6.8 Hz, 2H), 1.32–1–25 (m, 6H), 1.07 (quint,  $J$  = 6.8 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD)  $\delta$  173.1, 171.4, 170.6, 169.4, 164.7, 158.8, 148.2, 146.0, 144.9, 144.0, 141.8, 139.5, 136.5, 134.7, 133.4, 132.7, 132.5, 129.7, 129.4, 129.1, 128.8, 128.3, 127.3, 127.0, 126.0, 125.4, 124.1, 121.6, 121.1, 120.4, 114.8, 113.7, 70.4, 70.2, 70.1, 69.5, 69.4, 67.5, 63.7, 52.3, 51.9, 50.2, 47.1, 39.3, 30.9, 29.7, 28.4, 28.3, 26.2, 25.9, 22.7 ppm; HRMS (ESI)  $m/z$  calcd for C<sub>51</sub>H<sub>58</sub>N<sub>11</sub>O<sub>9</sub> [M + H]<sup>+</sup> 968.44190, found 968.4411.

3'-(1-(1-(2-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (U13). The compound was prepared from alkyne 56. The crude was purified using EtOAc and EtOAc/MeOH 9:1 as eluents. White solid; yield 50%; IR (neat) 3232, 3139, 3057, 2921, 2854, 1693, 1634, 1602, 1550, 1433, 1201, 1099, 752 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  9.02 (br s, 1H), 8.51 (d,  $J$  = 4.0 Hz, 1H), 8.44 (s, 1H), 8.26 (dt,  $J$  = 8.0, 1.9 Hz, 1H), 8.03 (s, 1H), 7.76 (d,  $J$  = 8.0 Hz, 1H), 7.64 (d,  $J$  = 7.5 Hz, 1H), 7.51–7.44 (m, 4H), 7.40–7.35 (m, 2H), 7.23 (t,  $J$  = 8.2 Hz, 1H), 6.98–6.96 (m, 2H), 6.88–6.85 (m, 1H), 5.37 (s, 2H), 5.12 (dd,  $J$  = 13.2/5.2 Hz, 1H), 4.64 (s, 2H), 4.47–

4.43 (m, 4H), 4.10 (t,  $J$  = 4.9 Hz, 2H), 3.80 (t,  $J$  = 4.8 Hz, 2H), 3.68–3.60 (m, 12H), 3.14 (t,  $J$  = 6.9 Hz, 2H), 2.92–2.83 (m, 1H), 2.79–2.72 (m, 1H), 2.46–2.35 (m, 1H), 2.16–2.10 (m, 1H), 1.93 (quint,  $J$  = 7.0 Hz, 2H), 1.34–1.23 (m, 6H), 1.07 (quint,  $J$  = 7.2 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD)  $\delta$  173.1, 171.4, 170.6, 169.4, 164.7, 158.8, 148.2, 146.0, 144.9, 144.1, 141.8, 139.5, 136.5, 134.6, 133.4, 132.7, 132.6, 129.7, 129.4, 129.1, 128.8, 127.4 (2C), 127.0, 126.0, 125.4, 124.1, 121.7, 121.1, 120.4, 114.9, 113.7, 70.4, 70.2 (2C), 70.2, 70.1, 69.5, 69.4, 67.4, 63.7, 52.3, 51.9, 50.2, 47.1, 39.3, 30.9, 29.7, 28.4, 28.3, 26.2, 25.9, 22.7 ppm; HRMS (ESI)  $m/z$  calcd for C<sub>53</sub>H<sub>62</sub>N<sub>11</sub>O<sub>10</sub> [M + H]<sup>+</sup> 1012.46811, found 1012.46742.

## Synthesis of NAMPT Targeting PROTACs U14–21

**Synthesis of (2S,4R)-1-((S)-2-(4-Azidobutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (61).** NaN<sub>3</sub> (1.20 g, 15.4 mmol, 1.2 equiv) was added portionwise to a solution of ethyl 4-bromobutanoate (3.00 g, 15.4 mmol, 1 equiv) in DMF (28 mL) and the reaction was stirred overnight at 80 °C. Upon completion, the reaction was diluted with water and extracted with EtOAc (×3). The combined organic layers were washed with water (×2), brine (×1), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated under vacuum to give ethyl 4-azidobutanoate (59) as a colorless oil (1.04 g 43% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  4.03 (q,  $J$  = 4.1 Hz, 2H), 3.25 (t,  $J$  = 6.7 Hz, 2H), 2.30 (t,  $J$  = 7.3 Hz, 2H), 1.81 (q,  $J$  = 6.9 Hz, 2H), 1.16 (t,  $J$  = 7.2 Hz, 3H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.5, 60.3, 50.5, 31.0, 24.1, 14.0 ppm.

LiOH (0.48 g, 19.9 mmol, 3 equiv) was added to a solution of 59 (1.04 g, 6.61 mmol, 1 equiv) in a solution of THF–water 1:1 (10 mL) and the reaction was stirred overnight at 40 °C. Upon completion, the reaction was quenched by adding 3 M HCl aqueous solution (pH ~ 1–2) and then extracted with EtOAc (×4). The combined organic layers were then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was evaporated under vacuum to afford 4-azidobutanoic acid (60) as a colorless oil (0.83 g 98% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.55 (br s, 1H), 3.36 (t,  $J$  = 6.72 Hz, 2H), 2.46 (t,  $J$  = 7.28 Hz, 2H), 1.90 (quint,  $J$  = 6.97 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.1, 50.4, 30.9, 23.9 ppm.

DIPEA (0.533 mL, 3.06 mmol, 4.5 equiv) and HATU (0.323 g, 0.850 mmol, 1.25 equiv) were added to a solution of 60 (0.0877 g, 0.680 mmol, 1 equiv) in DMF (10 mL) and it was stirred at room temperature for 5 min. Subsequently VHL ligand 10 (0.370 g, 0.680 mmol, 1 equiv) was added portionwise and the reaction was stirred at room temperature for 5 h under nitrogen atmosphere. Upon completion, the reaction was diluted with brine and extracted with EtOAc (×2). The combined organic layers were washed with brine (×1), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated under vacuum. The reaction crude was then purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 and CH<sub>2</sub>Cl<sub>2</sub>/MeOH 97:3 as eluents. Azide 61 was obtained as a pale yellow solid (0.266 g 72% yield); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  8.88 (s, 1H), 8.66 (t,  $J$  = 5.9 Hz, 1H), 7.92 (d,  $J$  = 8.8 Hz, 1H), 7.47 (d,  $J$  = 8.2 Hz, 2H), 7.42 (d,  $J$  = 8.2 Hz, 2H), 4.66–4.53 (m, 4H), 4.41–4.36 (m, 1H), 3.95–3.80 (m, 2H), 3.37–3.34 (m, 2H), 2.48 (s, 3H), 2.43–2.33 (m, 2H), 2.27–2.07 (m, 2H), 1.86 (quint,  $J$  = 7.2 Hz, 2H), 1.06 (s, 9H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) Chemical shifts were referred to the main rotamer  $\delta$  173.5, 173.0, 170.9, 151.5, 147.6, 138.9, 132.0, 130.1, 129.0, 127.6, 69.7, 59.4, 57.8, 56.6, 50.5, 42.3, 37.5, 35.1, 32.1, 25.7, 24.7, 14.5 ppm; HRMS (ESI)  $m/z$  calcd for C<sub>26</sub>H<sub>36</sub>N<sub>7</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 542.25495, found 542.25461.

**General Procedure B1 for the Click Reaction.** Azide 61 (1.2 equiv), sodium ascorbate (1 equiv), CuSO<sub>4</sub>·5H<sub>2</sub>O (0.2 equiv) were added to a solution of the corresponding alkyne (62, 44–46, 53–56) (1 equiv) in a mixture of THF–H<sub>2</sub>O 2:1 (0.08 M) and the reaction was stirred for 5 h at 25 °C. Upon completion, the reaction was diluted with water and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (×3). The combined organic layers were washed with 1% EDTA aqueous solution (basified to pH 10 with few drops of 2 M NaOH) (×1) and water (×1). The solvent was evaporated under vacuum and the crude was purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 and CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1 as eluents.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)methyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U14**). The compound was prepared from alkyne **62**. White solid; yield 53%; IR (neat) 3293, 3066, 2929, 2858, 1630, 1526, 1434, 1194, 1010, 790, 759, 697  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.00 (br s, 1H), 8.67 (s, 1H), 8.54 (br s, 1H), 8.25 (d,  $J = 7.5$  Hz, 1H), 8.07 (s, 1H), 7.73 (s, 1H), 7.65 (d,  $J = 7.2$  Hz, 1H), 7.48–7.28 (m, 10H), 7.02–6.94 (m, 3H), 6.73 (d,  $J = 8.3$  Hz, 1H), 5.41 (br s, 1H), 5.16 (s, 2H), 4.76 (t,  $J = 7.8$  Hz, 1H), 4.59–4.31 (m, 8H), 4.07 (d,  $J = 11.2$  Hz, 1H), 3.62 (d,  $J = 8.4$  Hz, 1H), 3.10 (q,  $J = 6.1$  Hz, 2H), 2.51–2.48 (m, 4H), 2.30–2.18 (m, 5H), 1.92 (quint,  $J = 6.5$  Hz, 2H), 1.22–1.12 (m, 6H), 1.00–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.8 (2C), 170.9, 169.6, 158.2, 150.3, 148.8, 148.4, 146.8, 144.5, 143.6, 141.8, 139.0, 138.2, 136.0, 133.2, 131.6, 130.9, 130.0 (2C), 129.9, 129.5, 128.6, 128.0, 127.8, 127.1, 123.9, 123.8, 121.6, 120.4, 114.8, 114.6, 70.0, 61.7, 58.6, 57.9, 56.8, 50.4, 49.2, 43.2, 39.6, 36.4, 35.1, 32.3, 30.1, 28.8, 28.5, 26.4, 26.3, 26.1, 25.8, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{56}\text{H}_{67}\text{N}_{12}\text{O}_6\text{S}$  [M + H]<sup>+</sup> 1035.50272, found 1035.50167.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U15**). The compound was prepared from alkyne **44**. White solid; yield 47%; IR (neat) 3272, 3067, 2928, 2857, 1632, 1531, 1434, 1204, 1020, 759, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.00 (br s, 1H), 8.67 (br s, 2H), 8.25 (d,  $J = 6.9$  Hz, 1H), 8.04 (s, 1H), 7.65 (d,  $J = 7.3$  Hz, 1H), 7.54–6.98 (m, 11H), 6.92–6.85 (m, 3H), 6.78 (br s, 1H), 5.39 (br s, 1H), 4.76 (br s, 1H), 4.59–4.32 (m, 8H), 4.31 (br s, 2H), 4.08 (d,  $J = 11.1$  Hz, 1H), 3.62 (d,  $J = 9.0$  Hz, 1H), 3.18–3.09 (m, 4H), 2.50 (br s, 4H), 2.28–2.17 (m, 5H), 1.92 (quint,  $J = 6.7$  Hz, 2H), 1.26–1.11 (m, 6H), 0.97–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 171.4, 171.0, 169.6, 158.6, 150.3, 148.8, 148.4, 146.8, 144.5, 144.3, 141.7, 139.0, 138.2, 135.9, 133.1, 131.6, 130.8, 130.0 (2C), 129.8, 129.4, 128.6, 128.2, 128.0, 127.7, 122.6 (2C), 121.2, 120.3, 115.2, 113.7, 70.0, 66.8, 58.6, 57.9, 56.8, 50.4, 49.0, 43.1, 39.7, 36.4, 35.1, 32.3, 30.1, 28.8, 28.5, 26.5, 26.4, 26.2, 26.1, 26.0, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{57}\text{H}_{69}\text{N}_{12}\text{O}_6\text{S}$  [M + H]<sup>+</sup> 1049.51837, found 1049.51786.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)propyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U16**). The compound was prepared from alkyne **45**. White solid; yield 56%; IR (neat) 3291, 3067, 2930, 2860, 1630, 1530, 1435, 1202, 1052, 791, 760, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.67 (br s, 1H), 8.29 (br s, 1H), 8.03 (s, 1H), 7.67 (d,  $J = 7.3$  Hz, 1H), 7.46–7.29 (m, 11H), 6.98 (d,  $J = 7.3$  Hz, 1H), 6.89–6.86 (m, 3H), 5.41 (br s, 1H), 4.78–4.36 (m, 9H), 4.09 (d,  $J = 10.9$  Hz, 1H), 4.00 (br s, 1H), 3.63 (d,  $J = 10.2$  Hz, 1H), 3.12 (q,  $J = 6.0$  Hz, 2H), 2.89 (br s, 2H), 2.50 (br s, 4H), 2.16 (br s, 7H), 1.94 (br s, 2H), 1.27–1.16 (m, 6H), 1.00–0.95 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 171.7, 171.1, 169.6, 158.9, 150.3, 148.4 (2C), 146.9, 144.8 (2C), 141.7, 139.2, 138.2, 135.9, 132.9, 131.8, 130.8, 130.0 (2C), 129.7, 129.4, 128.6, 128.2, 128.0, 127.7, 121.7 (2C), 121.0, 120.4, 114.5, 114.3, 70.0, 67.0, 58.7, 57.9, 56.8, 50.4, 49.0, 43.1, 39.7, 36.6, 35.3, 32.4, 30.1, 28.8 (2C), 28.5, 26.5, 26.4, 26.2, 25.9, 22.1, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{58}\text{H}_{71}\text{N}_{12}\text{O}_6\text{S}$  [M + H]<sup>+</sup> 1063.53402, found 1063.53299.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)butyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U17**). The compound was prepared from alkyne **46**. White solid; yield 61%; IR (neat) 3291, 3066, 2929, 2860, 1629, 1432, 1434, 1201, 1051, 791, 759, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.65 (br s, 1H), 8.23 (d,  $J = 5.9$  Hz, 1H), 7.98 (s, 1H), 7.66 (d,  $J = 7.4$  Hz, 1H), 7.45–7.25 (m, 11H), 6.96–6.84 (m, 3H), 6.70 (br s, 1H), 5.41 (t,  $J = 5.5$  Hz, 1H), 4.75 (br s, 1H), 4.52–4.33 (m, 8H), 4.06–3.97 (m, 3H), 3.65–3.61 (m, 1H), 3.12 (q,  $J = 6.3$  Hz, 2H), 2.75 (br s, 2H), 2.49 (br s, 4H), 2.24–2.14 (m, 5H), 1.93–1.83 (m, 6H), 1.26–1.15 (m, 6H), 1.05–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR  $\delta$  171.9, 171.6, 171.1, 169.5, 159.0, 150.3, 148.8,

148.4, 146.5, 144.7, 141.7, 139.2, 138.2, 135.8, 132.9, 131.7, 130.8, 130.0, 129.9, 129.7, 129.4, 128.7, 128.2, 128.0, 127.7, 121.4 (2C), 121.0, 120.4, 114.7, 114.0, 70.0, 67.6, 58.7, 57.9, 56.8, 50.4, 49.0, 43.1, 39.7, 36.6, 35.3, 32.4, 30.1, 28.8, 28.7, 28.5, 26.5, 26.4, 26.2, 26.0, 25.9, 25.3, 16.0 ppm. HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{59}\text{H}_{73}\text{N}_{12}\text{O}_6\text{S}$  [M + H]<sup>+</sup> 1077.54967, found 1077.54962.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U18**). The compound was prepared from alkyne **53**. White solid; yield 59%; IR (neat) 3293, 3065, 2921, 2853, 1631, 1531, 1436, 1201, 1089, 1051, 759, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.03 (br s, 1H), 8.66 (s, 1H), 8.55 (br s, 1H), 8.28 (d,  $J = 7.9$  Hz, 1H), 8.05 (s, 1H), 7.66 (dd,  $J = 7.4/1.1$  Hz, 1H), 7.63 (s, 1H), 7.49–7.26 (m, 10H), 6.99 (d,  $J = 7.6$  Hz, 1H), 6.93 (s, 1H), 6.87 (dd,  $J = 8.2/1.9$  Hz, 1H), 6.76 (d,  $J = 8.5$  Hz, 1H), 5.42 (t,  $J = 5.6$  Hz, 1H), 4.78–4.32 (m, 11H), 4.14–4.07 (m, 3H), 3.89–3.87 (m, 2H), 3.64–3.61 (m, 1H), 3.14 (q,  $J = 6.2$  Hz, 2H), 2.66 (br s, 1H), 2.50–2.42 (m, 4H), 2.28–2.14 (m, 5H), 1.90 (quint,  $J = 7.0$  Hz, 2H), 1.27–1.17 (m, 6H), 1.01–0.89 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 171.6, 171.1, 169.6, 158.7, 150.3, 148.5, 148.4, 146.4, 144.8, 144.3, 141.7, 139.1, 138.2, 135.9, 133.5, 131.6, 130.8, 130.0 (2C), 129.7, 129.4, 128.7, 128.0, 127.7, 127.2, 124.0, 123.4, 121.4, 120.5, 114.8, 114.1, 70.0, 68.8, 67.4, 64.6, 58.7, 57.9, 56.9, 50.4, 49.1, 43.1, 39.7, 36.5, 35.2, 32.3, 30.1, 28.8, 28.5, 26.5, 26.3, 26.2, 25.9, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{58}\text{H}_{71}\text{N}_{12}\text{O}_7\text{S}$  [M + H]<sup>+</sup> 1079.52894, found 1079.52824.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U19**). The compound was prepared from alkyne **54**. White solid; yield 76%; IR (neat) 3293, 3068, 2926, 2859, 1630, 1529, 1436, 1201, 1087, 1056, 842  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.98 (br s, 1H), 8.63 (s, 1H), 8.49 (br s, 1H), 8.20 (d,  $J = 6.8$  Hz, 1H), 8.02 (s, 1H), 7.60–7.56 (m, 3H), 7.43–7.22 (m, 9H), 6.94 (d,  $J = 7.5$  Hz, 1H), 6.88–6.83 (m, 3H), 5.66 (br t, 1H), 4.70 ( $J = 7.8$  Hz, 1H), 4.57–4.25 (m, 11H), 4.08–3.57 (m, 10H), 3.11 (q,  $J = 6.1$  Hz, 2H), 2.46 (s, 3H), 2.32–2.03 (m, 6H), 1.89 (quint,  $J = 6.4$  Hz, 2H), 1.25–1.16 (m, 6H), 1.00–0.92 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.2, 171.5, 171.3, 169.7, 158.7, 150.3, 148.5, 148.3, 146.5, 144.7, 144.3, 141.6, 139.1, 138.3, 135.9, 133.4, 131.6, 130.7, 130.0 (2C), 129.7, 129.4, 128.5, 128.0, 127.7, 127.2, 124.0, 123.4, 121.4, 120.6, 114.9, 113.9, 70.6, 70.1, 69.6, 69.6, 67.4, 64.3, 58.8, 58.2, 56.7, 50.4, 49.1, 43.0, 39.7, 36.8, 35.1, 32.2, 30.1, 28.8, 28.5, 26.5, 26.3, 26.1, 25.9, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{60}\text{H}_{75}\text{N}_{12}\text{O}_8\text{S}$  [M + H]<sup>+</sup> 1123.55515, found 1123.55526.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)butanamido)butanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (**U20**). The compound was prepared from alkyne **55**. White solid; yield 55%; IR (neat) 3294, 3067, 2924, 2857, 1633, 1531, 1435, 1202, 1087, 1054, 760, 708  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.04 (br s, 1H), 8.68 (s, 1H), 8.56 (br s, 1H), 8.31 (d,  $J = 7.8$  Hz, 1H), 8.03 (s, 1H), 7.68–7.63 (m, 2H), 7.48–7.26 (m, 10H), 6.98 (d,  $J = 7.6$  Hz, 1H), 6.93 (s, 1H), 6.87 (dd,  $J = 8.2/1.9$  Hz, 1H), 6.78 (d,  $J = 8.3$  Hz, 1H), 5.47 (t,  $J = 5.6$  Hz, 1H), 4.76 (t,  $J = 8.2$  Hz, 1H), 4.60–4.32 (m, 11H), 4.12–4.07 (m, 3H), 3.85–3.82 (m, 2H), 3.72–3.62 (m, 9H), 3.15 (q,  $J = 6.2$  Hz, 2H), 2.51–2.35 (m, 4H), 2.25–2.11 (m, 5H), 1.95–1.90 (m, 2H), 1.27–1.19 (m, 6H), 1.04–0.95 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.1, 171.6, 171.2, 169.9, 158.8, 150.3, 148.7, 148.3, 146.6, 144.8, 144.4, 141.7, 139.1, 138.3, 135.9, 133.3, 131.6, 130.7, 130.0, 129.9, 129.6, 129.4, 128.6, 128.0, 127.7, 127.0, 124.0, 123.5, 121.4, 120.4, 114.8, 114.1, 70.7, 70.4 (2C), 70.0, 69.7 (2C), 67.4, 64.4, 58.8, 58.0, 56.9, 50.4, 49.0, 43.1, 39.7, 36.7, 35.2, 32.1, 30.1, 28.8, 28.5, 26.4, 26.4, 26.2, 25.9, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{62}\text{H}_{79}\text{N}_{12}\text{O}_9\text{S}$  [M + H]<sup>+</sup> 1167.58137, found 1167.58039.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(4-(4-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-

2,5,8,11-tetraoxatridecyl)-1H-1,2,3-triazol-1-yl)butanamido-butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (U21). The compound was prepared from alkyne 56. White solid; yield 61%; IR (neat) 3294, 3067, 2927, 2859, 1632, 1529, 1436, 1202, 1088, 1055, 760, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.99 (br s, 1H), 8.64 (s, 1H), 8.51 (br s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.60–7.32 (m, 12H), 6.91–6.85 (m, 4H), 5.54 (br s, 1H), 4.70–4.38 (m, 11H), 4.09–4.02 (m, 3H), 3.81–3.61 (m, 15H), 3.12 (br s, 2H), 2.47–2.12 (m, 9H), 1.90 (br s, 2H), 1.24 (br s, 6H), 0.93 (br s, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.8, 171.6, 171.2, 169.5, 158.8, 150.3, 148.8, 148.4, 146.7, 145.0, 144.4, 141.7, 139.1, 138.3, 135.9, 133.2, 131.6, 130.8, 130.0, 129.9, 129.6, 129.4, 128.7, 128.0, 127.7, 127.0, 123.9, 121.3, 120.2, 114.7, 114.2, 70.7, 70.5, 70.0, 69.7, 67.5, 67.2, 58.6, 57.6, 56.7, 50.4, 43.1, 39.7, 36.7, 36.2, 35.1, 30.2, 28.8, 28.5, 26.4 (2C), 26.2, 16.0 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{64}\text{H}_{83}\text{N}_{12}\text{O}_{10}\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  1211.60758, found 1211.60853.

### Synthesis of NAMPT Targeting PROTACs U22–29

Ethers 71–74 were synthesized from phenol 8 and the corresponding tosylated poly(ethylene glycol) *tert*-butyl ester (67–70) following the general procedure A. The crude were purified by column chromatography using  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  98:2 as eluent.

**General Procedure C for the *tert*-Butyl Ester Hydrolysis (75–78).** The corresponding *tert*-butyl ester (71–74) (1 equiv) was dissolved in a 4 N HCl solution in dioxane (0.2 M), and the reaction was stirred at 25 °C for 1 h. Upon completion, the solvent was evaporated under vacuum and the reaction crude was purified by column chromatography using  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  95:5 and  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  9:1.

**General Procedure D for the Amide Coupling.** VHL ligand 10 or lenalidomide (9) (1.1 equiv) and DIPEA (6 equiv) were added to a solution of the corresponding carboxylic acid (75–78) (1 equiv) in DMF (0.033 M). The solution was cooled to 0 °C, then HATU (1.5 equiv) was added. The reaction mixture was stirred at 25 °C for 5 h under nitrogen atmosphere. Upon completion, the reaction was diluted with water and extracted with  $\text{CH}_2\text{Cl}_2$  ( $\times 2$ ). The combined organic layers were washed with water ( $\times 1$ ), brine ( $\times 1$ ), dried over anhydrous  $\text{Na}_2\text{SO}_4$  and the solvent was evaporated under vacuum. The crude was purified by column chromatography using  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  98:2 and  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  9:1 as eluents.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(3-(2-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (U22). The compound was prepared from carboxylic acid 75. White solid; yield: 78%; IR (neat) 3294, 3067, 2927, 2860, 1632, 1526, 1434, 1199, 1110, 1050, 759, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.02 (br s, 1H), 8.64 (s, 1H), 8.53 (br s, 1H), 8.28 (d,  $J = 8.0$  Hz, 1H), 8.05 (s, 1H), 7.62 (dd,  $J = 1.4/1.4$  Hz, 1H), 7.51–7.24 (m, 10H), 7.03–6.85 (m, 4H), 5.51 (t,  $J = 5.8$  Hz, 1H), 4.66 (t,  $J = 8.0$  Hz, 1H), 4.55–4.28 (m, 6H), 4.12–4.05 (m, 2H), 3.99 (d,  $J = 11.2$  Hz, 1H), 3.81–3.59 (m, 6H), 3.16–3.10 (m, 2H), 2.50–2.36 (m, 6H), 2.12–2.05 (m, 1H), 1.95–1.88 (quint,  $J = 7.0$  Hz, 2H), 1.26–1.15 (m, 6H), 1.04–0.93 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.6, 171.4, 171.1, 169.6, 158.7, 150.3, 148.4, 148.3, 146.3, 144.3, 141.7, 139.2, 138.3, 135.9, 133.6, 131.6, 130.8, 130.0 (2C), 129.7, 129.4, 128.6, 128.0, 127.7, 127.3, 124.1, 121.3, 120.5, 144.5, 114.4, 70.0, 69.6, 67.3 (2C), 58.6, 57.6, 56.8, 50.4, 43.1, 39.7, 36.8, 36.3, 35.3, 30.1, 28.8, 28.5, 26.4, 26.3, 26.2, 16.0 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{54}\text{H}_{66}\text{N}_9\text{O}_7\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  984.48059, found 984.47881.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(3-(2-(2-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (U23). The compound was prepared from carboxylic acid 76. White solid; yield 58%; IR (neat) 3295, 3065, 2925, 2859, 1632, 1528, 1435, 1200, 1088, 759, 697  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.99 (br s, 1H), 8.63 (s, 1H), 8.53 (br s, 1H), 8.22 (d,  $J = 7.9$  Hz, 1H), 7.98 (s, 1H), 6.64 (d,  $J = 7.4$  Hz, 1H), 7.51–7.24 (m, 10H), 7.07–6.86 (m, 4H), 5.50 (t,  $J = 5.7$  Hz, 1H), 4.69 (t,  $J = 7.9$  Hz, 1H), 4.55–4.27 (m, 6H), 4.10–4.08 (m, 2H),

4.02 (d,  $J = 11.3$  Hz, 1H), 3.81 (t,  $J = 4.8$  Hz, 2H), 3.71–3.59 (m, 7H), 3.13 (q,  $J = 6.7$  Hz, 2H), 2.48–2.40 (m, 6H), 2.13–2.08 (m, 1H), 1.92 (quint,  $J = 7.0$  Hz, 2H), 1.26–1.16 (m, 6H), 1.05–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.7, 171.6, 171.0, 169.5, 158.8, 150.3, 149.0, 148.4, 146.9, 144.6, 141.7, 139.1, 138.2, 135.9, 133.0, 131.6, 130.8, 130.0, 129.9, 129.6, 129.4, 128.7, 128.0, 127.7, 127.0, 123.9, 121.3, 120.2, 114.7, 114.2, 70.7, 70.5, 70.0, 69.7, 67.5, 67.2, 58.6, 57.6, 56.7, 50.4, 43.1, 39.7, 36.7, 36.2, 35.1, 30.2, 28.8, 28.5, 26.4 (2C), 26.2, 16.0 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{56}\text{H}_{70}\text{N}_9\text{O}_8\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  1028.50681, found 1028.50459.

(2*S*,4*R*)-1-((*S*)-14-(*tert*-Butyl)-12-oxo-1-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-3,6,9-trioxo-13-azapentadecan-15-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (U24). The compound was prepared from carboxylic acid 77. White solid; yield 51%; IR (neat) 3293, 3066, 2922, 2860, 1629, 1528, 1437, 1200, 1087, 841  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.00 (br s, 1H), 8.64 (s, 1H), 8.52 (br s, 1H), 8.21 (d,  $J = 7.7$  Hz, 1H), 7.99 (s, 1H), 7.63 (d,  $J = 7.4$  Hz, 1H), 7.49–7.24 (m, 10H), 7.05–6.87 (m, 4H), 5.59 (t,  $J = 5.5$  Hz, 1H), 4.66 (t,  $J = 8.0$  Hz, 1H), 4.53–4.30 (m, 6H), 4.11 (t,  $J = 4.2$  Hz, 2H), 3.98 (d,  $J = 11.2$  Hz, 1H), 3.83–3.82 (m, 2H), 3.68–3.54 (m, 11H), 3.14 (q,  $J = 6.5$  Hz, 2H), 2.49–2.33 (m, 6H), 2.11–2.04 (m, 1H), 1.90 (quint,  $J = 7.2$  Hz, 2H), 1.26–1.18 (m, 6H), 1.04–1.03 (m, 2H), 0.93 (s, 9H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.1, 171.6, 171.1, 169.7, 158.7, 150.3, 148.9, 148.4, 146.9, 144.5, 141.7, 139.1, 138.3, 135.9, 133.1, 131.6, 130.8, 130.1, 130.0, 129.7, 129.4, 128.6, 128.0, 127.7, 127.0, 123.9, 121.4, 120.4, 114.9, 114.2, 70.5, 70.2 (3C), 70.0, 69.6, 67.5, 67.1, 58.7, 57.9, 56.6, 50.4, 43.1, 39.7, 36.4, 36.3, 35.0, 30.1, 28.8, 28.5, 26.4 (2C), 26.2, 16.1 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{58}\text{H}_{74}\text{N}_9\text{O}_9\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  1072.53302, found 1072.53095.

(2*S*,4*R*)-1-((*S*)-17-(*tert*-Butyl)-15-oxo-1-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (U25). The compound was prepared from carboxylic acid 78. White solid; yield 58%; IR (neat) 3306, 3065, 2923, 2857, 1632, 1530, 1435, 1201, 1088, 841  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.01 (br s, 1H), 8.66 (s, 1H), 8.53 (br s, 1H), 8.21 (d,  $J = 7.9$  Hz, 1H), 7.99 (s, 1H), 7.63 (d,  $J = 7.4$  Hz, 1H), 7.46–7.24 (m, 10H), 6.99–6.87 (m, 4H), 5.52 (t,  $J = 5.6$  Hz, 1H), 4.66 (t,  $J = 7.9$  Hz, 1H), 4.54–4.30 (m, 6H), 4.14–4.11 (m, 2H), 4.02–4.00 (m, 1H), 3.87–3.84 (m, 2H), 3.73–3.70 (m, 2H), 3.65–3.58 (m, 13H), 3.14 (q,  $J = 6.7$  Hz, 2H), 2.49 (s, 3H), 2.44–2.41 (m, 3H), 2.17–2.09 (m, 1H), 1.92 (quint,  $J = 6.9$  Hz, 2H), 1.26–1.17 (m, 6H), 1.05–0.93 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.2, 171.5, 171.0, 169.6, 158.8, 150.3, 149.0, 148.4, 146.9, 144.5, 141.7, 139.1, 138.3, 135.9, 133.1, 131.6, 130.8, 130.1, 130.0, 129.7, 129.4, 128.6, 128.0, 127.7, 127.0, 123.9, 121.4, 120.3, 114.8, 114.2, 70.4, 70.2, 70.1 (4C), 70.0, 69.6, 67.5, 67.1, 58.6, 57.8, 56.6, 50.4, 43.1, 39.7, 36.4, 36.3, 35.0, 30.2, 28.8, 28.5, 26.4 (2C), 26.2, 16.1 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{60}\text{H}_{78}\text{N}_9\text{O}_{10}\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  1116.55924, found 1116.55836.

3'-(2-(3-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-3-oxopropoxy)ethoxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (U26). The compound was prepared from carboxylic acid 75. White solid; yield 43%; IR (neat) 3270, 3064, 2925, 2855, 1683, 1637, 1539, 1431, 1201, 1121, 1052, 753  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.42 (s, 1H), 9.08 (s, 1H), 8.99 (s, 1H), 8.53 (d,  $J = 4.0$  Hz, 1H), 8.20 (d,  $J = 7.9$  Hz, 1H), 7.94 (s, 1H), 7.67 (d,  $J = 6.7$  Hz, 1H), 7.58 (t,  $J = 6.7$  Hz, 2H), 7.44–7.18 (m, 6H), 6.94 (d,  $J = 7.5$  Hz, 1H), 6.88 (s, 1H), 6.78 (d,  $J = 6.6$  Hz, 1H), 5.66 (t,  $J = 5.4$  Hz, 1H), 5.03 (dd,  $J = 13.0/4.8$  Hz, 1H), 4.39–4.35 (m, 4H), 4.13 (br s, 2H), 3.89–3.84 (m, 4H), 3.12 (q,  $J = 6.2$  Hz, 2H), 2.71–2.68 (m, 3H), 2.28–2.11 (m, 2H), 2.03–2.00 (m, 1H), 1.87 (quint,  $J = 7.0$  Hz, 2H), 1.21–1.20 (m, 6H), 1.00–0.98 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.8, 170.1, 170.0, 169.9, 169.0, 158.6, 148.8, 146.7, 144.5, 141.8, 139.1, 135.9, 134.0, 133.2, 133.0, 132.5, 130.1, 130.0, 129.7, 128.9, 128.4, 127.7, 127.0, 126.0, 123.9, 121.4, 120.6, 120.3, 114.9, 114.4, 69.7, 67.5, 67.3, 51.9, 50.4, 46.6, 39.7, 37.2, 31.5, 30.1, 28.8, 28.4, 26.3, 26.1, 23.2 ppm; HRMS (ESI)  $m/z$  calcd for  $\text{C}_{45}\text{H}_{49}\text{N}_8\text{O}_7$  [ $\text{M} + \text{H}$ ] $^+$  813.37242, found 813.37079.

3'-(2-(2-(3-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-3-oxopropoxy)ethoxy)ethoxy)-N-(7-(4-(pyridin-3-yl)-1H-

1,2,3-triazol-1-yl)heptyl]-[1,1'-biphenyl]-2-carboxamide (**U27**). The compound was prepared from carboxylic acid **76**. White solid; yield 40%; IR (neat) 3270, 3052, 2920, 1683, 1636, 1537, 1431, 1200, 1104, 1053, 752 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.03 (br s, 1H), 8.52–8.50 (m, 2H), 8.28 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.57–7.36 (m, 7H), 7.21 (t, J = 8.9 Hz, 1H), 7.00–6.95 (m, 1H), 6.90 (s, 1H), 6.79 (dd, J = 8.2/2.2 Hz, 1H), 5.13 (dd, J = 13.3/5.2 Hz, 1H), 4.49–4.44 (m, 4H), 3.12 (t, J = 6.7 Hz, 2H), 2.92–2.83 (m, 1H), 2.77–2.72 (m, 1H), 2.67 (t, J = 5.9 Hz, 2H), 2.42 (qd, J = 13.2/4.6 Hz, 1H), 2.16–2.12 (m, 1H), 1.92 (quint, J = 6.8 Hz, 2H), 1.30–1.24 (m, 6H), 1.03–1.02 (m, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 173.2, 171.5, 171.0, 170.6, 169.6, 158.6, 148.1, 145.8, 143.9, 141.7, 139.4, 136.5, 134.8, 135.5, 133.1, 132.4, 129.8, 129.4, 129.0, 128.6, 127.4, 127.3, 127.0, 126.2, 124.2, 121.7, 121.0, 120.0, 114.5, 113.4, 70.2, 70.0, 69.4, 67.2, 66.7, 52.2, 50.2, 47.0, 39.3, 36.6, 31.0, 29.8, 28.4, 28.3, 26.2, 25.9, 22.8 ppm; HRMS (ESI) *m/z* calcd for C<sub>47</sub>H<sub>53</sub>N<sub>8</sub>O<sub>7</sub> [M + H]<sup>+</sup> 857.39864, found 857.39694.

3'-(2-(2-(2-(3-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-3-oxopropoxy)ethoxy)ethoxy)ethoxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U28**). The compound was prepared from carboxylic acid **77**. White solid; yield 9%; IR (neat) 3271, 3067, 2921, 2852, 1685, 1601, 1535, 1457, 1200, 1085, 1053, 750 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.04 (br s, 1H), 8.52 (br s, 2H), 8.29 (d, J = 8.0 Hz, 1H), 7.76–7.72 (m, 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.56–7.44 (m, 5H), 7.30–7.26 (m, 2H), 6.91–6.84 (m, 2H), 5.16 (dd, J = 13.5/5.1 Hz, 1H), 4.50–4.46 (m, 4H), 4.03–4.01 (m, 2H), 3.82 (t, J = 5.9 Hz, 2H), 3.73–3.71 (m, 2H), 3.64–3.61 (m, 8H), 3.15 (br s, 2H), 2.95–2.86 (m, 1H), 2.81–2.76 (m, 1H), 2.66 (t, J = 5.9 Hz, 2H), 2.45 (qd, J = 13.3/4.8 Hz, 1H), 2.20–2.16 (m, 1H), 1.95 (quint, J = 6.9 Hz, 2H), 1.33–1.30 (m, 6H), 1.14–1.12 (m, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 173.2, 171.1, 170.6, 170.3, 169.6, 157.3, 148.1, 145.8, 143.9, 140.0, 137.3, 136.7, 134.9, 133.5, 133.2, 132.5, 130.5, 129.8, 129.4, 128.7, 127.7, 127.4, 127.1, 126.3, 124.3, 121.7, 120.0 (2C), 117.2, 115.2, 70.3, 70.1, 70.0, 69.9, 69.3, 67.6, 66.7, 52.2, 50.2, 47.0, 39.1, 36.6, 31.0, 29.8, 28.7, 28.3, 26.2, 25.9, 22.8 ppm; HRMS (ESI) *m/z* calcd for C<sub>49</sub>H<sub>57</sub>N<sub>8</sub>O<sub>9</sub> [M + H]<sup>+</sup> 901.42485, found 901.42354.

N-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-1-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-3,6,9,12-tetraoxapentadecan-15-amide (**U29**). The compound was prepared from carboxylic acid **78**. White solid; yield 14%; IR (neat) 3292, 3065, 2921, 2852, 1686, 1638, 1539, 1432, 1201, 1095, 1026, 753 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.04 (br s, 1H), 8.54–8.52 (m, 2H), 8.31–8.28 (m, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.55–7.38 (m, 6H), 7.23 (t, J = 7.1 Hz, 1H), 7.00–6.97 (m, 2H), 6.88–6.85 (m, 1H), 5.16 (dd, J = 13.3/5.2 Hz, 1H), 4.54–4.44 (m, 4H), 4.11–4.08 (m, 2H), 3.85–3.78 (m, 4H), 3.65–3.54 (m, 12H), 3.15–3.12 (m, 2H), 2.95–2.86 (m, 1H), 2.81–2.75 (m, 1H), 2.66 (t, J = 5.9 Hz, 2H), 2.51–2.40 (qd, J = 13.2/4.8 Hz, 1H), 2.21–2.15 (m, 1H), 1.94 (quint, J = 7.0 Hz, 2H), 1.31–1.27 (m, 6H), 1.04–1.01 (m, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 173.2, 171.5, 171.4, 170.6, 169.6, 158.7, 148.1, 145.9, 143.9, 141.8, 139.5, 136.5, 134.9, 135.5, 133.2, 132.5, 129.7, 129.4, 129.0, 128.7, 127.4, 127.3, 127.0, 126.3, 124.2, 121.8, 121.0, 120.0, 114.6, 113.5, 70.3, 70.1 (3C), 70.0, 69.9, 69.4, 67.2, 66.7, 52.2, 47.0, 39.3, 36.6, 31.0, 29.8, 28.4, 28.3, 26.2, 25.9, 22.8 ppm; HRMS (ESI) *m/z* calcd for C<sub>51</sub>H<sub>61</sub>N<sub>8</sub>O<sub>10</sub> [M + H]<sup>+</sup> 945.45107, found 945.44842.

### Synthesis of NAMPT Targeting PROTACs U30–42

Ethers **91–96** were synthesized from phenol **8** and the corresponding bromo-ester (**85–90**) with addition of NaI (0.5 equiv) following the general procedure A.

**General Procedure E for the Basic Hydrolysis of Esters (97–102).** To a stirred solution of the corresponding methyl ester (**91–96**) (1 equiv) in THF/H<sub>2</sub>O 1:1 (0.05 M), was added LiOH (4 equiv) and the mixture was heated to 45 °C for 4 h. After completion of the reaction, water was added and the resulting aqueous phase was acidified with 2 M HCl until pH ~ 3. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (×3). The combined organic layers were washed with brine (×1), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude was

purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 and CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1 as eluents.

Finally, the carboxylic acids (**97–102**) were coupled with VHL ligand **10** or lenalidomide (**9**) overnight following the general procedure D.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(7-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-heptanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U30**). The compound was prepared from **97**. White solid; yield 63%; IR (neat) 3303, 3066, 2930, 2858, 1630, 1528, 1434, 1201, 847, 759 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.03 (br s, 1H), 8.69 (s, 1H), 8.55 (br s, 1H), 8.31 (d, J = 7.8 Hz, 1H), 8.10 (s, 1H), 7.70 (d, J = 7.4 Hz, 1H), 7.49–7.28 (m, 10H), 6.98–6.86 (m, 3H), 6.30 (d, J = 8.6 Hz, 1H), 5.32 (br s, 1H), 4.72 (t, J = 7.9 Hz, 1H), 4.61–4.54 (m, 3H), 4.44–4.33 (m, 3H), 4.08 (br d, 1H), 3.92 (t, J = 6.1 Hz, 2H), 3.63–3.60 (m, 1H), 3.16–3.15 (m, 2H), 2.57–2.52 (m, 4H), 2.24–2.12 (m, 3H), 1.95 (quint, J = 6.7 Hz, 2H), 1.75 (quint, J = 6.6 Hz, 2H), 1.64 (quint, J = 7.2 Hz, 2H), 1.53–1.15 (m, 10H), 1.00–0.94 (m, 11H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.4, 171.8, 170.9, 169.5, 159.1, 150.3, 148.7, 148.4, 146.7, 144.5, 141.7, 139.3, 138.2, 135.8, 133.2, 131.6, 130.9, 130.0 (2C), 129.7, 129.5, 128.7, 128.1, 127.7, 127.2, 124.0, 120.8, 120.3, 114.5, 114.3, 69.9, 67.8, 58.7, 57.3, 56.9, 50.5, 43.2, 39.7, 36.3, 36.1, 35.2, 30.2, 29.0 (2C), 28.9, 28.8, 28.6, 26.4, 26.2, 25.8, 25.5, 16.0 ppm; HRMS (ESI) *m/z* calcd. for C<sub>56</sub>H<sub>70</sub>N<sub>9</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 996.51698, found 996.51558.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(8-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-octanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U31**). The compound was prepared from **98**. White solid; yield 53%; IR (neat) 3291, 3066, 2927, 2855, 1629, 1529, 1435, 1201, 759, 697 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.00 (br s, 1H), 8.66 (s, 1H), 8.54 (br s, 1H), 8.24 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.67 (d, J = 7.2 Hz, 1H), 7.47–7.26 (m, 10H), 6.96–6.84 (m, 3H), 6.36 (d, J = 8.8 Hz, 1H), 5.40 (t, J = 5.4 Hz, 1H), 4.72 (t, J = 7.9 Hz, 1H), 4.59–4.42 (m, 3H), 4.41–4.31 (m, 4H), 4.06–4.03 (m, 1H), 3.91 (t, J = 6.4 Hz, 2H), 3.65–3.61 (m, 1H), 3.14 (q, J = 6.3 Hz, 2H), 2.50–2.40 (m, 4H), 2.34–2.11 (m, 3H), 1.92 (quint, J = 6.9 Hz, 2H), 1.73 (quint, J = 6.8 Hz, 2H), 1.59 (quint, J = 6.9 Hz, 2H), 1.42–1.14 (m, 12H), 1.04–0.94 (m, 11H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.5, 171.8, 171.0, 169.5, 159.1, 150.3, 148.9, 148.4, 146.8, 144.6, 141.7, 139.3, 138.2, 135.8, 133.1, 131.6, 130.9, 130.0 (2C), 129.7, 129.5, 128.8, 128.1, 127.7, 127.1, 124.0, 120.8, 120.2, 114.6, 114.2, 69.9, 67.9, 58.7, 57.3, 56.9, 50.4, 43.2, 39.7, 36.4, 36.1, 35.2, 30.2, 29.1, 29.0, 28.9, 28.8, 28.5, 26.4, 26.3, 26.2, 25.8, 25.5, 16.0 ppm; HRMS (ESI) *m/z* calcd. for C<sub>57</sub>H<sub>72</sub>N<sub>9</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 1010.53263, found 1010.53113.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(9-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-nonanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U32**). The compound was prepared from **99**. White solid; yield 40%; IR (neat) 3288, 3067, 2927, 2855, 1629, 1527, 1436, 1201, 759, 698 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.00 (br s, 1H), 8.67 (s, 1H), 8.53 (d, J = 1.3 Hz, 1H), 8.25 (dt, J = 8.0/1.9 Hz, 1H), 8.00 (s, 1H), 7.69 (dd, J = 7.5/1.3 Hz, 1H), 7.48–7.26 (m, 10H), 6.97–6.86 (m, 3H), 6.32 (d, J = 8.8 Hz, 1H), 5.37 (t, J = 5.6 Hz, 1H), 4.72 (t, J = 7.9 Hz, 1H), 4.59–4.53 (m, 3H), 4.41 (t, J = 7.2 Hz, 2H), 4.37–4.32 (m, 1H), 4.27 (br s, 1H), 4.06 (br d, 1H), 3.92 (t, J = 6.4 Hz, 2H), 3.64–3.61 (m, 1H), 3.14 (q, J = 6.2 Hz, 2H), 2.51–2.45 (m, 4H), 2.20–2.11 (m, 3H), 1.93 (quint, J = 7.0 Hz, 2H), 1.74 (quint, J = 6.8 Hz, 2H), 1.59 (quint, J = 6.2 Hz, 2H), 1.40 (quint, J = 7.7 Hz, 2H), 1.29–1.15 (m, 12H), 1.05–0.94 (m, 11H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.6, 171.8, 170.9, 169.4, 159.2, 150.3, 148.9, 148.4, 146.8, 144.6, 141.7, 139.3, 138.1, 135.7, 133.1, 131.6, 130.9, 130.0 (2C), 129.7, 129.5, 128.8, 128.1, 127.7, 127.0, 123.9, 120.8, 120.1, 114.6, 114.2, 69.9, 68.0, 58.7, 57.3, 56.9, 50.5, 43.2, 39.7, 36.5, 36.0, 35.2, 30.2, 29.2 (3C), 29.1, 29.0, 28.8, 28.5, 26.4, 26.2, 26.0, 25.6, 16.0 ppm; HRMS (ESI) *m/z* calcd. for C<sub>58</sub>H<sub>74</sub>N<sub>9</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 1024.54828, found 1024.54812.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(10-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)-

decanamido)butanoyl-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U33**). The compound was prepared from **100**. White solid; yield 67%; IR (neat) 3290, 3065, 2925, 2854, 1628, 1528, 1434, 1201, 1028, 759, 697  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.00 (br s, 1H), 8.67 (s, 1H), 8.54 (br s, 1H), 8.25 (d,  $J = 7.9$  Hz, 1H), 7.98 (s, 1H), 7.69 (d,  $J = 7.4$  Hz, 1H), 7.47–7.26 (m, 10H), 6.97–6.87 (m, 3H), 6.32 (d,  $J = 8.5$  Hz, 1H), 5.37 (br s, 1H), 4.72 (t,  $J = 7.8$  Hz, 1H), 4.58–4.53 (m, 3H), 4.41 (t,  $J = 7.1$  Hz, 2H), 4.37–4.32 (m, 1H), 4.08–4.05 (m, 1H), 3.93 (t,  $J = 6.4$  Hz, 2H), 3.65–3.61 (m, 1H), 3.14 (q,  $J = 6.4$  Hz, 2H), 2.51 (br s, 4H), 2.20–2.14 (m, 3H), 1.93 (quint,  $J = 6.9$  Hz, 2H), 1.75 (quint,  $J = 7.0$  Hz, 2H), 1.58–1.51 (m, 2H), 1.44–1.15 (m, 16H), 1.04–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.7, 171.8, 170.9, 169.4, 159.2, 150.3, 148.7, 148.4, 146.6, 144.5, 141.7, 139.3, 138.1, 135.7, 133.3, 131.6, 130.9, 130.1, 130.0, 129.7, 129.5, 128.8, 128.1, 127.7, 127.1, 124.0, 120.9, 120.2, 114.6, 114.2, 69.9, 68.0, 58.7, 57.3, 56.9, 50.5, 43.2, 39.7, 36.5, 36.0, 35.1, 30.2, 29.7, 29.3, 29.2, 29.2, 28.8, 28.5, 26.4, 26.3, 26.0, 25.6, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{39}\text{H}_{76}\text{N}_9\text{O}_6\text{S}$   $[\text{M} + \text{H}]^+$  1038.56393, found 1038.56175.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(11-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)undecanamido)butanoyl-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U34**). The compound was prepared from **101**. White solid; yield 51%; IR (neat) 3294, 3066, 2922, 2852, 1628, 1528, 1434, 1201, 844, 759, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.01 (br s, 1H), 8.68 (s, 1H), 8.57 (d,  $J = 4$  Hz, 1H), 8.25 (d,  $J = 7.8$  Hz, 1H), 7.96 (s, 1H), 7.72 (d,  $J = 7.4$  Hz, 1H), 7.49–7.28 (m, 10H), 6.98–6.89 (m, 3H), 6.19 (d,  $J = 8.6$  Hz, 1H), 5.30 (br s, 1H), 4.73 (t,  $J = 7.9$  Hz, 1H), 4.61–4.53 (m, 3H), 4.43 (t,  $J = 7.1$  Hz, 2H), 4.38–4.33 (m, 1H), 4.13–4.11 (m, 1H), 3.95 (t,  $J = 6.4$  Hz, 2H), 3.63–3.60 (m, 1H), 3.18–3.13 (q,  $J = 6.4$  Hz, 2H), 2.60–2.53 (m, 4H), 2.21–2.12 (m, 3H), 1.97–1.92 (quint,  $J = 6.9$  Hz, 2H), 1.77 (quint,  $J = 7.1$  Hz, 2H), 1.59 (br s, 2H), 1.50–1.44 (m, 4H), 1.28–1.19 (m, 14H), 1.06–0.95 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.8, 171.9, 170.8, 169.4, 159.2, 150.3, 149.0, 148.5, 146.8, 144.6, 141.7, 139.3, 138.1, 135.7, 133.1, 131.6, 131.0, 130.0 (2C), 129.7, 129.5, 128.8, 128.1, 127.7, 127.0, 123.9, 120.8, 120.1, 114.6, 114.2, 70.0, 68.0, 58.5, 57.4, 56.8, 50.5, 43.3, 39.7, 36.5, 35.8, 35.0, 30.2, 29.4, 29.3 (2C), 29.2 (3C), 29.1, 28.8, 28.5, 26.4, 26.2, 26.0, 25.6, 16.0 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{60}\text{H}_{78}\text{N}_9\text{O}_6\text{S}$   $[\text{M} + \text{H}]^+$  1052.57958, found 1052.57738.

(2*S*,4*R*)-1-((*S*)-3,3-Dimethyl-2-(12-((2'-((7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)dodecanamido)butanoyl-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide (**U35**). The compound was prepared from **102**. White solid; yield 35%; IR (neat) 3285, 3069, 2922, 2853, 1630, 1528, 1435, 1201, 759, 697  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.01 (br s, 1H), 8.68 (s, 1H), 8.57 (br s, 1H), 8.25 (d,  $J = 7.9$  Hz, 1H), 7.96 (s, 1H), 7.71 (d,  $J = 7.5$  Hz, 1H), 7.49–7.28 (m, 10H), 6.98–6.88 (m, 3H), 6.20 (br d, 1H), 5.31 (br s, 1H), 4.74 (t,  $J = 7.8$  Hz, 1H), 4.61–4.54 (m, 3H), 4.42 (t,  $J = 7.1$  Hz, 2H), 4.38–4.33 (m, 1H), 4.11–4.08 (br d, 1H), 3.95 (t,  $J = 6.5$  Hz, 2H), 3.64–3.60 (m, 1H), 3.15 (q,  $J = 6.4$  Hz, 2H), 2.57–2.52 (m, 4H), 2.21–2.15 (m, 3H), 1.94 (quint,  $J = 7.0$  Hz, 4H), 1.77 (quint,  $J = 7.0$  Hz, 2H), 1.59 (br s, 2H), 1.44 (quint,  $J = 6.8$  Hz, 2H), 1.26–1.18 (m, 16H), 1.06–0.94 (m, 11H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.7, 172.0, 170.7, 169.4, 159.2, 150.3, 149.0, 148.5, 146.9, 144.6, 141.7, 139.3, 138.1, 135.7, 133.1, 131.6, 131.0, 130.1, 130.0, 129.7, 129.5, 128.9, 128.1, 127.7, 127.0, 123.9, 120.8, 120.0, 114.6, 114.2, 70.0, 68.0, 58.5, 57.4, 56.8, 50.5, 43.3, 39.7, 36.5, 35.8, 35.0, 30.2, 29.4, 29.4, 29.3, 29.2 (3C), 29.1, 28.9, 28.5, 26.4, 26.3, 26.0, 25.5, 16.1 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{61}\text{H}_{80}\text{N}_9\text{O}_6\text{S}$   $[\text{M} + \text{H}]^+$  1066.59523, found 1066.59612.

3'-((7-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-7-oxoheptyl)oxy)-N-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U36**). The compound was prepared from **97**. White solid; yield 49%; IR (neat) 3269, 3068, 2928, 2856, 1686, 1638, 1529, 1429, 1200, 752, 726, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.23 (s, 1H), 8.99 (br s, 2H), 8.55 (br s, 1H), 8.19 (d,  $J = 7.6$  Hz, 1H), 7.95 (s, 1H), 7.71–7.63 (m, 3H), 7.47–7.52 (m, 6H), 6.96–6.83 (m, 3H), 5.53 (br s, 1H), 5.07 (dd,  $J = 12.9/4.8$  Hz, 1H), 4.41–4.33 (m, 4H), 3.90 (t,  $J = 5.7$  Hz, 2H), 3.14 (q,  $J = 6.0$  Hz,

2H), 2.78–2.66 (m, 2H), 2.42 (t,  $J = 7.0$  Hz, 2H), 2.19–2.09 (m, 2H), 1.91–1.89 (m, 2H), 1.74 (br s, 4H), 1.43 (br s, 4H), 1.23–1.19 (m, 6H), 1.00 (br d, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.2, 175.6, 170.0, 169.8, 169.1, 159.1, 148.8, 146.6, 144.5, 141.6, 139.3, 135.8, 134.1, 133.3, 133.3, 132.6, 130.1 (2C), 129.7, 128.9, 128.5, 127.7, 126.9, 126.2, 124.0, 120.7, 120.5, 120.3, 114.9, 114.1, 67.9, 51.8, 50.5, 46.8, 39.7, 36.6, 31.5, 30.1, 28.8 (2C), 28.5, 26.3, 26.1, 25.6, 25.4, 23.2 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{47}\text{H}_{53}\text{N}_8\text{O}_6$   $[\text{M} + \text{H}]^+$  825.40881, found 825.40767.

3'-((8-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-8-oxooctyl)oxy)-N-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U37**). The compound was prepared from **98**. White solid; yield 39%; IR (neat) 3256, 3066, 2923, 2853, 1682, 1639, 1601, 1534, 1430, 1201, 1051, 793, 751, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.01 (s, 2H), 8.90 (s, 1H), 8.57 (br s, 1H), 8.21 (d,  $J = 7.9$  Hz, 1H), 7.93 (s, 1H), 7.68–7.63 (m, 3H), 7.49–7.27 (m, 6H), 6.96 (d,  $J = 7.7$  Hz, 1H), 6.89–6.86 (m, 2H), 5.43 (t,  $J = 5.7$  Hz, 1H), 5.13 (dd,  $J = 13.1/5.2$  Hz, 1H), 4.46–4.36 (m, 4H), 3.92 (t,  $J = 6.4$  Hz, 2H), 3.15 (q,  $J = 6.2$  Hz, 2H), 2.83–2.69 (m, 2H), 2.43 (t,  $J = 7.3$  Hz, 2H), 2.29–2.18 (m, 1H), 2.14–2.11 (m, 1H), 1.92 (quint,  $J = 7.0$  Hz, 2H), 1.74 (t,  $J = 6.6$  Hz, 2H), 1.46–1.38 (m, 6H), 1.27–1.15 (m, 6H), 1.00 (quint,  $J = 7.0$  Hz, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.1, 171.4, 169.8, 169.7, 169.1, 159.1, 148.9, 146.6, 144.6, 141.6, 139.3, 135.7, 134.4, 133.3, 133.2, 132.7, 130.1, 130.0, 129.8, 128.9, 128.6, 127.7, 127.0, 126.2, 124.0, 120.7, 120.6, 120.2, 114.7, 114.3, 68.0, 51.8, 50.5, 46.8, 39.8, 36.6, 31.5, 30.2, 28.9, 28.8, 28.8, 28.7, 28.5, 26.4, 26.2, 25.9, 25.4, 23.3 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{48}\text{H}_{55}\text{N}_8\text{O}_6$   $[\text{M} + \text{H}]^+$  839.42446, found 839.42275.

3'-((9-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-9-oxononyl)oxy)-N-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U38**). The compound was prepared from **99**. Off-white solid; yield 53%; IR (neat) 3270, 3065, 2925, 2852, 1677, 1638, 1534, 1430, 1200, 1051, 751, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.01 (br s, 1H), 8.89 (s, 1H), 8.71 (s, 1H), 8.57 (br s, 1H), 8.22 (d,  $J = 7.7$  Hz, 1H), 7.94 (s, 1H), 7.68–7.65 (m, 3H), 7.49–7.28 (m, 6H), 6.97 (d,  $J = 7.3$  Hz, 1H), 6.89–6.87 (m, 2H), 5.40 (br t, 1H), 5.14 (dd,  $J = 13.1/4.9$  Hz, 1H), 4.45–4.40 (m, 4H), 3.93 (t,  $J = 6.2$  Hz, 2H), 3.15 (q,  $J = 6.3$  Hz, 2H), 2.85–2.70 (m, 2H), 2.42 (t,  $J = 7.1$  Hz, 2H), 2.28–2.16 (m, 2H), 1.93 (quint,  $J = 6.6$  Hz, 2H), 1.79–1.74 (m, 4H), 1.43–1.17 (m, 14H), 1.02–1.00 (m, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.3, 171.7, 170.1, 169.7, 169.1, 159.1, 148.9, 146.7, 144.5, 141.6, 139.3, 135.7, 134.2, 133.4, 133.2, 132.6, 130.1 (2C), 129.7, 128.9, 128.6, 127.7, 126.9, 126.2, 124.0, 120.7, 120.5, 120.3, 114.8, 114.1, 68.0, 51.8, 50.5, 46.8, 39.7, 36.8, 31.5, 30.2, 29.0 (2C), 29.0 (2C), 28.8, 28.5, 26.4, 26.2, 25.8, 25.6, 23.2 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{49}\text{H}_{57}\text{N}_8\text{O}_6$   $[\text{M} + \text{H}]^+$  853.44011, found 853.43877.

3'-((10-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-10-oxodecyl)oxy)-N-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U39**). The compound was prepared from **100**. Off-white solid; yield 35%; IR (neat) 3260, 3065, 2926, 2854, 1686, 1639, 1601, 1534, 1430, 1201, 1050, 793, 752, 698  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.19 (br s, 1H), 9.00 (s, 1H), 8.80 (br s, 1H), 8.55 (d,  $J = 3.9$  Hz, 1H), 8.20 (dt,  $J = 6.1/1.8$  Hz, 1H), 7.94 (s, 1H), 7.69–7.63 (m, 3H), 7.48–7.27 (m, 6H), 6.95 (d,  $J = 7.7$  Hz, 1H), 6.89–6.86 (m, 2H), 5.47 (t,  $J = 5.6$  Hz, 1H), 5.09 (dd,  $J = 13.1/5.2$  Hz, 1H), 4.42–4.37 (m, 4H), 3.92 (t,  $J = 6.4$  Hz, 2H), 3.14 (q,  $J = 6.2$  Hz, 2H), 2.80–2.70 (m, 2H), 2.40 (t,  $J = 7.4$  Hz, 2H), 2.24–2.08 (m, 2H), 1.92 (quint,  $J = 7.0$  Hz, 2H), 1.77–1.68 (m, 4H), 1.41–1.15 (m, 16H), 1.01 (quint,  $J = 6.8$  Hz, 2H) ppm;  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.3, 171.6, 170.0, 169.6, 169.1, 159.2, 148.8, 146.6, 144.5, 141.6, 139.3, 135.6, 134.2, 133.3, 133.2, 132.6, 130.1 (2C), 129.7, 128.9, 128.7, 127.7, 127.0, 126.2, 124.0, 120.8, 120.6, 120.2, 114.8, 114.1, 68.0, 51.8, 50.5, 46.8, 39.7, 38.8, 31.5, 30.2, 29.2, 29.1, 29.0, 28.9, 28.8, 28.5, 26.4, 26.2, 25.9, 25.6, 23.2 ppm; HRMS (ESI)  $m/z$  calcd. for  $\text{C}_{50}\text{H}_{59}\text{N}_8\text{O}_6$   $[\text{M} + \text{H}]^+$  867.45576, found 867.45320.

3'-((11-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-11-oxoundecyl)oxy)-N-(7-(4-(pyridin-3-yl)-1*H*-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (**U40**). The compound was prepared from **101**. Off-white solid; yield 28%; IR (neat) 3269, 3058, 2923, 2852, 1686, 1639, 1535, 1453, 1430, 1201, 1050, 751, 698

cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.07 (s, 1H), 9.00 (s, 1H), 8.64 (s, 1H), 8.56 (br s, 1H), 8.19 (d, *J* = 7.9 Hz, 1H), 7.91 (s, 1H), 7.69–7.65 (m, 3H), 7.48–7.27 (m, 6H), 6.97–6.87 (m, 3H), 5.42 (t, *J* = 5.5 Hz, 1H), 5.10 (dd, *J* = 13.0/4.9 Hz, 1H), 4.42–4.38 (m, 4H), 3.93 (t, *J* = 6.3 Hz, 2H), 3.15 (q, *J* = 6.5 Hz, 2H), 2.80–2.66 (m, 2H), 2.40 (t, *J* = 7.3 Hz, 2H), 2.25–2.20 (m, 1H), 2.18–2.09 (m, 1H), 1.90 (quint, *J* = 7.1 Hz, 2H), 1.76–1.69 (m, 4H), 1.42–1.18 (m, 18H), 1.04–1.02 (m, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.2, 171.5, 169.9, 169.5, 169.1, 159.2, 149.0, 146.8, 144.6, 141.7, 139.3, 135.6, 134.2, 133.2, 133.1, 132.6, 130.1 (2C), 129.7, 128.9, 128.7, 127.7, 126.9, 126.2, 123.9, 120.8, 120.7, 120.1, 114.8, 114.2, 68.0, 51.8, 50.5, 46.8, 39.7, 36.8, 31.5, 30.1, 29.7, 29.3, 29.2, 29.1, 29.1 (2C), 28.8, 28.5, 26.4, 26.2, 26.0, 25.6, 23.2 ppm; HRMS (ESI) *m/z* calcd. for C<sub>51</sub>H<sub>61</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup> 881.47141, found 861.46948.

**3'-((12-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-amino)-12-oxododecyl)oxy)-N-(7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)-[1,1'-biphenyl]-2-carboxamide (U41).** The compound was prepared from **102**. Off-white solid; yield 35%; IR (neat) 3269, 3066, 2923, 2852, 1684, 1639, 1602, 1533, 1430, 1297, 1200, 1051, 751, 698 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.96 (s, 1H), 8.57 (br s, 1H), 8.52 (s, 1H), 8.22 (d, *J* = 7.5 Hz, 1H), 7.92 (s, 1H), 7.70–7.67 (m, 3H), 7.49–7.28 (m, 6H), 6.97–6.88 (m, 3H), 5.39 (br t, 1H), 5.13 (dd, *J* = 13.0/5.0 Hz, 1H), 4.43–4.40 (m, 4H), 3.94 (t, *J* = 6.2 Hz, 2H), 3.15 (q, *J* = 6.3 Hz, 2H), 2.84–2.70 (m, 2H), 2.41 (t, *J* = 7.3 Hz, 2H), 2.30–2.15 (m, 2H), 1.93 (quint, *J* = 6.6 Hz, 2H), 1.77–1.70 (m, 4H), 1.43–1.16 (m, 20H), 1.04 (quint, *J* = 6.7 Hz, 2H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.1, 171.4, 169.9, 169.5, 169.0, 159.2, 148.9, 146.7, 144.6, 141.6, 139.3, 135.6, 134.3, 133.2, 133.1, 132.7, 130.1 (3C), 129.7, 129.0, 128.8, 127.7, 127.0, 126.2, 124.0, 120.8, 120.1, 114.8, 114.1, 68.0, 51.8, 50.5, 46.7, 39.7, 36.9, 31.5, 30.2, 29.3 (3C), 29.2 (4C), 28.8, 28.5, 26.4, 26.2, 26.0, 25.6, 23.3 ppm; HRMS (ESI) *m/z* calcd. for C<sub>52</sub>H<sub>63</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup> 895.48706, found 895.48523.

**(2S,4R)-1-((S)-3,3-Dimethyl-2-(8-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)octanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (U42).** The compound was prepared from VHL ligand **103** and carboxylic acid **98** following the general procedure D. White solid, yield 84%; IR (neat) 3292, 3065, 2929, 2858, 1627, 1528, 1436, 1300, 1201, 759, 698 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.99 (s, 1H), 8.65 (s, 1H), 8.53 (d, *J* = 3.8 Hz, 1H), 8.24 (dt, *J* = 8.0, 1.9 Hz, 1H), 8.00 (s, 1H), 7.68 (dd, *J* = 7.5, 1.6 Hz, 1H), 7.46–7.25 (m, 11H), 6.95 (dt, *J* = 7.5, 1.2 Hz, 1H), 6.89 (t, *J* = 2.0 Hz, 1H), 6.85 (ddd, *J* = 8.3, 2.6, 1.0 Hz, 1H), 6.30 (d, *J* = 8.7 Hz, 1H), 5.30 (t, *J* = 6.0 Hz, 1H), 5.07 (quint, *J* = 7.1 Hz, 1H), 4.72 (t, *J* = 7.9 Hz, 1H), 4.59 (d, *J* = 8.8 Hz, 1H), 4.51 (brs, 1H), 4.40 (t, *J* = 7.2 Hz, 2H), 4.06 (dt, *J* = 11.5, 1.9 Hz, 1H), 3.91 (t, *J* = 6.4 Hz, 2H), 3.59 (dd, *J* = 11.3, 3.8 Hz, 1H), 3.13 (q, *J* = 6.7 Hz, 2H), 2.54–2.48 (m, 4H), 2.21–2.17 (m, 2H), 2.09–2.03 (m, 1H), 1.92 (quint, *J* = 7.2 Hz, 2H), 1.73 (quint, *J* = 6.6 Hz, 2H), 1.61 (q, *J* = 7.3 Hz, 2H), 1.46 (d, *J* = 6.9 Hz, 3H), 1.43–1.38 (m, 2H), 1.34–1.21 (m, 8H), 1.17 (quint, *J* = 7.3 Hz, 2H), 1.03–0.97 (m, 11H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.6, 172.2, 169.8, 169.5, 159.3, 150.4, 149.1, 148.6, 147.0, 144.7, 143.3, 141.8, 139.4, 135.9, 133.2, 131.7, 131.0, 130.2, 130.1, 129.8, 129.7, 128.9, 127.8, 127.2, 126.6, 124.0, 121.0, 120.3, 114.7, 114.3, 70.0, 68.0, 58.6, 57.6, 56.9, 50.6, 49.0, 39.8, 36.5, 35.6, 35.3, 30.4, 29.2, 29.2, 29.1, 29.0, 28.7, 26.6, 26.5, 26.4, 26.0, 25.6, 22.3, 16.2 ppm; HRMS (ESI) *m/z* calcd. for C<sub>58</sub>H<sub>74</sub>N<sub>9</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 1024.54828, found 1024.54811.

**(2S,4S)-1-((S)-3,3-Dimethyl-2-(8-((2'-((7-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)heptyl)carbamoyl)-[1,1'-biphenyl]-3-yl)oxy)octanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (U42-NC).** The compound was prepared from the commercially available (2S,4S)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (**104**), and carboxylic acid **98** following the general procedure D. White solid, yield 56%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.69 (s, 1H), 8.57 (s, 1H), 8.22 (d, *J* = 6.4 Hz, 1H), 7.90 (s, 1H), 7.71–7.65 (m, 2H), 7.48–7.27 (m, 10H), 6.98–6.87 (m, 3H), 6.19 (d, *J* = 8.8 Hz, 1H), 5.31 (brt, 1H), 5.09 (quint, *J* = 7.1 Hz, 1H), 4.75 (d, *J* = 8.8 Hz, 1H), 4.59 (d, *J* = 8.9 Hz, 1H), 4.47–4.41 (m, 3H), 3.95–3.82 (m, 4H), 3.15 (q, *J* = 6.3

Hz, 2H), 2.54 (s, 3H), 2.36–2.15 (m, 4H), 1.93 (quint, *J* = 6.9 Hz, 2H), 1.76 (quint, *J* = 6.4 Hz, 2H), 1.63 (brs, 2H), 1.52–1.18 (m, 15H), 1.07–1.04 (m, 11H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.1, 172.5, 171.5, 169.4, 159.2, 150.4, 149.1, 148.6, 147.0, 144.7, 142.3, 141.7, 139.2, 135.8, 133.0, 131.4, 131.2, 130.1, 130.0, 129.7 (2C), 128.8, 127.7, 126.9, 126.5, 123.8, 120.9, 119.9, 114.6, 114.2, 71.0, 68.0, 59.9, 58.6, 57.0, 50.4, 49.3, 39.6, 36.4, 35.1, 34.7, 30.2, 29.2 (2C), 29.0, 28.9, 28.5, 26.4, 26.3, 26.2, 25.9, 25.4, 21.9, 16.1 ppm; HRMS (ESI) *m/z* calcd. for C<sub>58</sub>H<sub>74</sub>N<sub>9</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 1024.54828, found 1024.54576.

## Cell Culturing

MCF7 human breast cancer cell line (ATCC HTB-22) and 4T1c5 murine triple-negative breast cancer cell line<sup>30</sup> were cultured in Minimum Essential Medium Eagle (MEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% glutamine (Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-Aldrich). All cells were maintained at 37 °C + 5% CO<sub>2</sub>.

## Western Blot Analysis

0.4 × 10<sup>6</sup> or 1.5 × 10<sup>5</sup> MCF7 and 4T1c5 cells were seeded respectively into a 6 or 12-well plate to be exposed, the day after plating, to different concentrations of the synthesized compounds, as detailed in the text. For experiments shown in Figure SA,B, bortezomib (300 nM, Sigma-Aldrich; #5043140001) was added 30 min before the treatment with PROTAC compounds. For experiments shown in Figure 6B,C, cells were treated with the lead compound **7** and ligand VHL-Ac. One hour later U42 was added.

Cells were lysed in RIPA buffer containing protease inhibitors (100 nM PMSF, Sigma-Aldrich; PIC, Merck-Millipore) and phosphatase inhibitors (1 M NaF; 1 M Na<sub>2</sub>VO<sub>4</sub>, Sigma-Aldrich). Lysates were centrifuged at 13,000 rpm for 15 min at 4 °C, and protein concentration was measured using the Bradford assay (Sigma-Aldrich). Proteins were resolved via SDS-PAGE and transferred to nitrocellulose membranes using the TurboBlot system (Bio-Rad, Hemel Hempstead, UK). Immunoblotting was performed with primary antibodies mouse anti-NAMPT mAb (AdipoGen; Cat# AG-20A-0034, RRID:AB\_2490117), anti-VHL mAb (Santa Cruz; Cat# sc-135657), NAPRT (Proteintech; Cat# 13549-1-AP) and mouse anti-Actin mAb (Sigma-Aldrich; #MAB1501), followed by HRP-conjugated antimouse secondary antibodies (Bio-Rad Laboratories). Protein levels were assessed using chemiluminescence detection with ECL solution (Thermo Fisher Scientific). The representative images and densitometry histograms were obtained by at least three independent experiments.

## MTT Assay

1.5 × 10<sup>4</sup> MCF7 or 1.0 × 10<sup>4</sup> 4T1c5 were seeded into 24-multiwell. The day after plating, cells were treated with compounds for 72 h. After the exposure to synthesize compounds, cells were washed with 1X PBS and incubated with 250 μg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) in Locke buffer for 1 h at 37 °C + 5% CO<sub>2</sub>. Isopropanol-HCl 0.1 M was used to solubilize formazan crystals, and the optic absorbance was assessed at 570 nm using a plate reader (Victor3 V, PerkinElmer Life Sciences). The represented data were obtained by at least three independent experiments.

## Mammosphere Cultures in Poly-HEMA

A total of 2 × 10<sup>3</sup> cells were seeded into 6-well plates precoated with 1.2% w/v poly(2-hydroxyethyl methacrylate) (poly-HEMA, Sigma-Aldrich) in 95% ethanol heated at 60 °C and prepared the day before on 6-multiwell to let it dry overnight. Cells were maintained for 8 days in MEM without FBS which has been completed with B27 supplement (Invitrogen™ Life technology, CA, USA), basic fibroblast growth factor-2 (bFGF-2, 10 ng/mL, PeproTech, Rocky Hill, NJ, USA), epidermal growth factor (EGF, 20 ng/mL, Sigma) and heparin sodium salt (0.0004%, Sigma).<sup>40</sup>

At the time of plating, cells were treated with a dose curve of U42 without any additional treatment during the time course of the experiment. Cultures were maintained at 37 °C + 5% CO<sub>2</sub> for 8 days. Inverted microscope was used to capture images. For every experimental condition at least five images of the well have been

taken to have a more representative overview of the well. The data of every single replicate were percentageised with the means of the control images for each independent experiment. To calculate the number and area of the mammospheres, ImageJ software was used by selecting every single mammosphere in each of the five images for every experimental condition. A total of four independent experiments were conducted, and data were pulled in the histograms.

For Western blot analysis, mammospheres were harvested by centrifuging the medium at 1,200 rpm for 5 min, followed by the lysis of the pellet. Lysates were then quantified. Proteins were resolved in SDS-PAGE and transferred to nitrocellulose membranes using the TurboBlot system, as described above for Western blot analysis.

### eNAMPT Detection Assays

**Western Blot.** MCF7 and 4T1 cells were plated at a concentration of  $0.4 \times 10^6$  in 6-well plate. The day after cells were treated for 18 h with a dose-dependent curve of U42. After this period, cells were washed in 1X PBS and cultured for 18 h in serum-free conditions treating again with U42. Media were then harvested and concentrated with cutoff (as described by Grolla et al.).<sup>40</sup> Concentrated media were then loaded for SDS-PAGE as described above. To monitor eNAMPT levels directly after 18 h of treatment, as shown in Figure S5B, the day after plating cells were washed in 1X PBS and cultured for 24 h in serum-free conditions treating with U42.

**ELISA Assay.** After 8 days of culture, mammospheres have been harvested by centrifugating at 1200 rpm for 5 min. The pellets were lysed in RIPA lysis buffer as described above for Western blot assay. Media were harvested and were concentrated with cutoff (as described by Grolla et al.).<sup>40</sup> eNAMPT levels were then evaluated with a commercially available sandwich enzyme-linked immunosorbent assay kit (ELISA kit from AdipoGen Inc.; Seoul Korea). Indeed, mammospheres could not be starved as it occurred for cells in 2D conditions, and to evaluate eNAMPT levels ELISA assay was used. eNAMPT levels reported in histograms are represented as a ratio between eNAMPT values from ELISA assay and the number of mammospheres for each experimental condition. The data of every single experiment were percentageised with the means of control condition. Finally, all the data from three independent experiments were pulled.

### NAMPT Inhibitory Activity Measurement

Wild type murine NAMPT and murine NMNAT isoform 2 were expressed and purified as described previously.<sup>41,42</sup> For IC<sub>50</sub> evaluation, the reaction mixtures contained 35 nM NAMPT (~2 μg/mL), 1 μM NMNAT2 (~40 μg/mL), 12.5 U/mL ADH, 0.55 mg/mL BSA, 25 mM MgCl<sub>2</sub>, 75 mM ethanol, 30 mM semicarbazide, 0.6 mM PRPP, 0.3 mM Nam, ATP 1.25 mM dissolved in 30 mM HEPES/NaOH, pH 7.5. Assays were carried out in 96-well plates using 200 μL per well. Each PROTAC was diluted in DMSO and added to the above reaction mixtures ranging from 5 nM to 4 μM, always at 1% DMSO final. Fluorescence readings (excitation at 340 nm and emission at 455 nm) were recorded for 1 h using a Sinergy HT microplate. Temperature control was set at 37 °C. Data outputs were processed by the integrated software and taken only under linearity (coeff reg > 0.985, usually 15–60 min of records). IC<sub>50</sub> values were next calculated via best fitting in Excel to the eq 1 below

$$\text{activity\%} = 1 / (1 + [I] / \text{IC}_{50}) \quad (1)$$

where “activity %” represents the NAMPT rate relative vs no inhibitor control (arbitrary fixed to 100%). After each assay, individual mixtures with higher concentrations of PROTACs were added with 0.25 mM NMN to see rapidly increasing rates in all cases; this excluded any interference by PROTACs on both ancillary enzymes NMNAT2 and ADH.

### NAPRT Inhibitory Activity Measurement

Recombinant human NAPRT (PMID: 21742010) was assayed in the presence of pure recombinant NadD, NadE obtained as described (PMID: 25223558). Assay mixtures contained the reagents listed above for NAMPT but NMNAT2 and Nam and, in addition, 20 mM K<sub>2</sub>HPO<sub>4</sub>, pH 7.5, 4.5 mM NH<sub>4</sub>Cl, ~40 μg/mL NadD (0.6 milliU/mL), ~30 μg/mL NadE (0.3 milliU/mL), and 0.3 mM Na that was used to

start the reactions. DMSO control alone at 1% final or mixed to 10 μM final of either 7 or U42 was included. Incubation was at 37 °C. Fluorescence measurements from the Sinergy HT microplate were handled as described above. The reaction mixtures were finally added with 0.25 mM NaMN to see rapidly increasing rates and thus exclude interference by PROTACs on the ancillary enzymes NadD, NadE, and ADH.

### Intracellular NAD<sup>+</sup> Level Measurement

Cellular NAD<sup>+</sup> levels were determined after perchlorate extraction and C18-HPLC analysis as previously described.<sup>43</sup>

### NAMPT-Degrading Competition Assay

After seeding MCF7 and 4T1 cells in 12-well plate, and following overnight incubation in complete MEM culture medium, cells were treated with the lead compound 7 (1 μM) and/or ligand VHL-Ac (300 μM). One hour later, 300 nM of U42 was added to the pretreated cells following the treatment scheme represented in Figure 6B,C. After 18 h cells were lysed as described above and Western blot assay was performed. Data are represented by two independent experiments.

### Cellular Thermal Shift Assay

10<sup>6</sup> MCF7 and 4T1 cells were plated in 60 mm Petri dish overnight. The day after, cells were treated with DMSO or 10 μM U14, U31, or U42 for 5 h. After 5 h, cells were harvested, followed by washing twice with PBS and divided into two aliquots, two for control cells and two for U42-treated cells. One aliquot for control and U42-treated cells was divided into 6 aliquots, 25 μL each. Two aliquots for every cell line of control U42-treated cells were heated at 37 °C. The remaining aliquots were heated at the indicated temperatures (54, 57, 60, 63, 66 °C) for 3 min. After heating, aliquots were immediately put on ice and then RIPA lysis buffer was added in ratio 1:1. After 30 min in ice, aliquots were then subjected to two snap-freeze cycles in liquid nitrogen. After thawing at room temperature, samples were centrifuged at 13000 rcf for 15 min at 4 °C. The resulting supernatants were collected, mixed with loading buffer, and analyzed by Western blot as described above. Data are represented by two independent experiments.

### Statistical Analysis

Graphical representations and statistical analyses were performed using GraphPad Prism software, with data presented as mean ± SEM *t* test parametric (using Welch's *t* test) was used to compare two column samples and a *p*-value <0.05 was considered statistically significant. For multiple comparisons one way ANOVA (Brown-Forsythe and Welch ANOVA) was used.

### In Vitro Metabolic Stability and Pharmacokinetics

**Materials.** Mouse and human liver microsomes, pooled Wistar Han, male MLM, 20 mg/mL and pooled mixed gender donors HLM, 20 mg/mL; CD1Mouse Whole Blood K2EDTA; human recovered plasma pooled K3EDTA were purchased from Tebubio Srl (Magenta, Italy).

**Incubation in Mouse and Human Plasma.** The standard incubation mixture (100 μL final volume) was carried out by dissolving the tested substrate (50 μM) in DMSO (5% final volume) in preincubated plasma at 37 °C. The mixture was shaken for 60 min at 37 °C. Control incubations were carried out without substrate. Each incubation was stopped by addition of 200 μL of ice-cold acetonitrile, vortexed, and centrifuged at 13,000 rpm for 10 min. The supernatants were analyzed by LC-UV.

**Incubation in Liver Microsomes.** The standard incubation mixture (250 μL final volume) was carried out in a 50 mM Tris (tris[hydroxymethyl]aminomethane) buffer (pH 7.4) containing 150 mM KCl, 1.5 mM, 3.3 mM MgCl<sub>2</sub>, 1.3 mM NADPNa<sub>2</sub>, 3.3 mM glucose 6-phosphate, 0.4 units/mL glucose 6-phosphate dehydrogenase, acetonitrile as cosolvent (1% of total volume), and the substrate (50 μM). After pre-equilibration of the mixture, an appropriate volume of microsomal suspension was added to give a final protein concentration of 1.0 mg/mL. The mixture was incubated for 60 min at 37 °C in a thermomixer with 700 rpm shaking. Control incubations were carried out without the presence of substrate, or NADPH-regenerating system, or microsomes. Each incubation was stopped by the addition of 250 μL of ice-cold acetonitrile, vortexed, and centrifuged at 13,000 rpm for 5

min prior analysis. For compound **U42** time-dependent substrate depletion experiments were carried out at the concentration of 5  $\mu\text{M}$  in the presence of 1 mM  $\beta\text{NADPH}$  in both MLM and HLM. Aliquots (50  $\mu\text{L}$ ) were withdrawn at 0–5–10–20–40–60 min and stopped by addition of 100  $\mu\text{L}$  of ice-cold acetonitrile, vortexed, and centrifuged at 13,000 rpm for 5 min. The supernatants were analyzed by HPLC-HRMS. The natural log of the percent remaining is plotted against time and the slope ( $k$ ) of the line determined. Half-life (minutes) and the clearance *in vitro* ( $\mu\text{L min}^{-1} \text{mg}^{-1}$ ) were calculated as follow

$$t_{1/2} = \frac{\ln 2}{k}$$

$$\text{CL}_{\text{in vitro}} = \frac{\ln 2}{t_{1/2}} \times \frac{1}{\text{microsomes} \left( \frac{\text{mg}}{\text{mL}} \right)} \times 1000$$

**Data Processing.** The metabolic stability of the compounds **U31** and **U42** was determined *in vitro* by measuring the residual peak area after incubation by LC-UV analysis (Section S108 in Supporting Information). Samples from compound **U42** were further processed by LC-HRMS equipment for metabolite profiling. Raw data files were processed using both Xcalibur and Compound Discoverer 3.3 software (Thermo Scientific) using a customized workflow for detection and identification of the expected and unknown metabolites (Section S110 in Supporting Information).

**In Vivo PK Studies.** Animals were managed in accordance with Italian regulation D.L. 26/2014 on use of animals for scientific purposes and experiments were authorized by the Italian version of Institutional Animal Care and Use Committee Statement (Ministry of Health, 81/2024-PR DB064.86) following strictly three Rs principles. 8-weeks old Balb/c female mice were dosed with **U42** and **U31** i.p. at 20 mg/kg. The compounds were dissolved using a formulation of 50% PEG and 50% saline. Compounds were then heated at 60 °C for 1 h and put in a rotary agitator overnight. After a single administration, 0.1 mL of blood was collected at 5, 15, 30 min and at 1, 2, 4, 8, 24, 48 h from the drug administration (2 mice for each time point). Blood samples collected with EDTA were centrifuged for 5 min at 8000 rpm at 4 °C to obtain plasma for the subsequent analysis.

**Sample Preparation for LC-HRMS Analysis.** Aliquot (50  $\mu\text{L}$ ) of each sample was diluted with 100  $\mu\text{L}$  of acetonitrile containing 250  $\mu\text{g/L}$  of **U30** as internal standard. Samples were centrifuged at 13,000 rpm for 10 min and the supernatant injected into the LC-HRMS system (Section S109 in Supporting Information for full instrumental set up). If the levels of analytes were over range, plasma samples were preventively diluted with blank plasma.

**Data Analysis.** Quantification compounds **U31** and **U42** was performed by using the calibration curves obtained with the corresponding working standards of the analytes and using **U30** as internal standard. The pharmacokinetic parameters were calculated by plotting the plasma concentration curves versus time obtained from the average values of two animals, using PK Solver 2.0.<sup>44</sup>

**Molecular Modeling.** Docking poses of compound **7** were reproduced following the previously described protocol. Conformer generation and docking were performed using OMEGA<sup>45,46</sup> and FRED,<sup>47–49</sup> respectively, within the active site of NAMPT (PDB ID: 2GVJ). The crystallographic water molecule was omitted, as it was not required to reproduce the reference ligand orientation. Binding interactions were analyzed to assess the  $\pi$ - $\pi$  stacking of the pyridine ring with Phe193 and Tyr18' and the potential hydrogen bonding of the triazole moiety with Ser275. The VHL structure was taken from the crystal complex (PDB ID: 7JTO), preserving the coordinates of the bound ligand **10** tail within the recognition pocket. Ternary complex models were generated using the PROTAC-model procedure, which integrates FRODOCK for protein-protein docking,<sup>50</sup> RosettaDock for structural refinement,<sup>51</sup> and RDKit for conformational sampling and linker generation.<sup>52</sup>

Molecular Dynamics simulations were conducted with the Desmond module of the Schrödinger Suite (version 2025-1).<sup>53</sup> Each ternary complex was solvated in a  $10 \times 10 \times 10 \text{ \AA}$  orthorhombic box of TIP3P water, neutralized with  $\text{Na}^+$  and  $\text{Cl}^-$  ions to 0.15 M ionic strength.

Systems were minimized (2000 steps; 50 kcal mol<sup>-1</sup> Å<sup>-2</sup> restraints) and gradually equilibrated under NPT conditions through (i) a 12 ps run at 10 K, (ii) heating to 300 K over 24 ps, and (iii) a 24 ps equilibration at 300 K without restraints. Production MD was carried out for 100 ns at 300 K and 1 atm. Trajectories from three independent replicas were analyzed for RMSD, RMSF, and protein-ligand contact profiles using Desmond Simulation Interaction Diagram tools.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01827>.

Representative images of Western blot analysis of PROTAC<sub>S</sub> **U1–41** and NAMPT degradation by **U23** at different time points (Figure S1); the inhibitory activity of selected compounds against the catalytic activity of recombinant NAMPT (Figure S2); NAPRT inhibition assays of compound **7** and **U42** (Figure S3); CETSA on 4T1 cells treated with **U31** and **U14** (Figure S4); protein levels of iNAMPT and eNAMPT after treatment with **U42** (Figure S5); drug concentration-time curve of **U31** and **U42** (mice, 20 mg/kg, i.p.) (Figures S6–S7); phase I metabolites of **U42** incubated in mouse and human liver microsomes (Table S1); molecular modeling section (Figure S8–S14); synthetic methods and <sup>1</sup>H NMR and <sup>13</sup>C NMR data of the intermediates; <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra and HRMS spectra of representative PROTAC<sub>S</sub>; purity evaluation of selected PROTAC<sub>S</sub> by HPLC-UV analysis; LC-UV method for metabolic stability evaluation; LC-HRMS method for pharmacokinetic analysis of **U31** and **U42**; LC-HRMS method for metabolites identification of **U42** in mouse and human liver microsomes, and related data (PDF)

SMILES molecular formula strings (CSV)

MD trajectory movies of the NAMPT-VHL ternary complexes containing **U14** (Movie S1)

VHL ternary complexes containing **U31** (Movie S2)

## ■ AUTHOR INFORMATION

### Corresponding Authors

**Ubalina Galli** – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; [orcid.org/0000-0003-1126-0142](https://orcid.org/0000-0003-1126-0142); Email: [ubaldina.galli@uniupo.it](mailto:ubaldina.galli@uniupo.it)

**Tracey Pirali** – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; [orcid.org/0000-0003-3936-4787](https://orcid.org/0000-0003-3936-4787); Email: [tracey.pirali@uniupo.it](mailto:tracey.pirali@uniupo.it)

### Authors

**Marianna Moro** – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy

**Federica Carolina Balestrero** – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy

**Giorgia Colombo** – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; Division of Haematology/Oncology Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York 10021, United States

Marco Koten – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy

Benedetta Roncaglio – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy

Armando A. Genazzani – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; Department of Drug Science and Technology, Università degli Studi di Torino, 10125 Torino, Italy

Silvio Aprile – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; Novanalitica Srls., 28100 Novara, Italy; [orcid.org/0000-0003-4804-9543](https://orcid.org/0000-0003-4804-9543)

Alberto Massarotti – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy; [orcid.org/0000-0001-9306-8845](https://orcid.org/0000-0001-9306-8845)

Giuseppe Orsomando – Department of Clinical Sciences (DISCO), Section of Biochemistry, Polytechnic University of Marche, 60131 Ancona, Italy

Ambra A. Grolla – Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, 28100 Novara, Italy

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.5c01827>

### Author Contributions

\*U.G. and M.M. contributed equally to this work. The manuscript was written through contributions of all authors and edited by all.

### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

This work is part of the project NODES that has received funding from the MUR–M4C2 1.5 of PNRR with grant agreement no. ECS00000036 (to T.P.). T.P. also acknowledges AIRC (IG 2023 - ID. 29452 project). The study was funded by AIRC2018 21842 to A.A. Genazzani. The publication is part of the project 20228YKCF2 of A.A. Grolla which has received funding from NextGeneration EU - MUR M4C2– PRIN 2022.

### ABBREVIATIONS USED

AUC, area under the concentration–time curve; CDCl<sub>3</sub>, deuterated chloroform; CD<sub>3</sub>OD, deuterated methanol; (CD<sub>3</sub>)<sub>2</sub>SO, deuterated dimethyl sulfoxide; CRBN, cereblon; C<sub>max</sub>, maximum concentration; DBU, 1,8-diazabicycloundec-7-ene; DC<sub>50</sub>, concentration causing 50% protein degradation; DIPEA, diisopropylethylamine; D<sub>max</sub>, maximal levels of degradation; DME, 1,2-dimethoxyethane; DMAP, dimethylaminopyridine; DMF, *N,N*-dimethylformamide; DMSO, dimethyl sulfoxide; DPPA, diphenylphosphoryl azide; EDCl, *N*-(3-(dimethylamino)propyl)-*N'*-ethylcarbodiimide hydrochloride; EDTA, ethylenediaminetetraacetic acid; EtOAc, ethyl acetate; eNAMPT, extracellular NAMPT; HATU, 1-[bis-(dimethylamino)-methylene]-1*H*-1,2,3-triazolo[4,5-*b*]-pyridinium 3-oxid hexafluorophosphate; HLM, human liver microsomes; HPLC, high-performance liquid chromatography; IC<sub>50</sub>, half-maximal inhibitory concentration; iNAMPT, intracellular NAMPT; i.p., intraperitoneal injection; LC-UV, liquid chromatography coupled to ultraviolet detector; LC-HRMS, liquid

chromatography coupled to high resolution mass spectrometry; MeOH, methanol; MLM, mouse liver microsomes; NAD<sup>+</sup>, nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; PROTACs, proteolysis-targeting chimeras; PK, pharmacokinetic; PE, petroleum ether; PEG, poly(ethylene glycol); T<sub>1/2</sub>, elimination half-life; TEA, triethylamine; THF, tetrahydrofuran; TsCl, tosyl chloride; UPS, ubiquitin-proteasome system; VHL, von Hippel-Lindau

### REFERENCES

- (1) Adamo, A.; Frusteri, C.; Pallotta, M. T.; Piralì, T.; Sartoris, S.; Ugel, S. Moonlighting proteins are important players in cancer immunology. *Front. Immunol.* **2021**, *11*, No. 613069.
- (2) Audrito, V.; Messina, V. G.; Deaglio, S. NAMPT and NAPRT: two metabolic enzymes with key roles in inflammation. *Front. Oncol.* **2020**, *10*, No. 358.
- (3) Travelli, C.; Colombo, G.; Aliotta, M.; Fagiani, F.; Fava, N.; De Sanctis, R.; Grolla, A. A.; Garcia, J. G. N.; Clemente, N.; Portararo, P.; Costanza, M.; Condorelli, F.; Colombo, M. P.; Sangaletti, S.; Genazzani, A. A. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer. *J. Immunother. Cancer* **2023**, *11*, No. e007010.
- (4) Moro, M.; Balestrero, F. C.; Colombo, G.; Torretta, S.; Clemente, N.; Ciccone, V.; Del Grosso, E.; Donnini, S.; Travelli, C.; Condorelli, F.; Sangaletti, S.; Genazzani, A. A.; Grolla, A. A. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) drives abnormal pericyte-rich vasculature in triple-negative breast cancer. *Angiogenesis* **2025**, *28*, No. 4.
- (5) Grolla, A. A.; Miggiano, R.; Di Marino, D.; Bianchi, M.; Gori, A.; Orsomando, G.; Gaudino, F.; Galli, U.; Del Grosso, E.; Muzzola, F.; Angeletti, C.; Guarnieri, M.; Torretta, S.; Calabrò, M.; Boumya, S.; Fan, X.; Colombo, G.; Travelli, C.; Rocchio, F.; Aronica, E.; Wohlschlegel, J. A.; Deaglio, S.; Rizzi, M.; Genazzani, A. A.; Garavaglia, S. A Nicotinamide phosphoribosyltransferase–GAPDH interaction sustains the stress-induced NMN/NAD<sup>+</sup> salvage pathway in the nucleus. *J. Biol. Chem.* **2020**, *295*, 3635–3651.
- (6) Galli, U.; Colombo, G.; Travelli, C.; Tron, G. C.; Genazzani, A. A.; Grolla, A. A. Recent advances in NAMPT inhibitors: a novel immunotherapeutic strategy. *Front. Pharmacol.* **2020**, *11*, 656.
- (7) Wen, F.; Gui, G.; Wang, X.; Ye, L.; Qin, A.; Zhou, C.; Zha, X. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives. *Bioorg. Med. Chem.* **2024**, *99*, No. 117595.
- (8) Misner, D. L.; Kauss, M. A.; Singh, J.; Uppal, H.; Bruening-Wright, A.; Liederer, B. M.; Lin, T.; McCray, B.; La, N.; Nguyen, T.; Sampath, D.; Dragovich, P. S.; O'Brien, T.; Zabka, T. S. Cardiotoxicity associated with nicotinamide phosphoribosyltransferase inhibitors in rodents and in rat and human-derived cells lines. *Cardiovasc. Toxicol.* **2017**, *17*, 307–318.
- (9) Montecuccio, B. F.; Cea, M.; Bauer, I.; Soncini, D.; Caffa, I.; Lasigliè, D.; Nahimana, A.; Uccelli, A.; Bruzzone, S.; Nencioni, A. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. *Curr. Drug Targets* **2013**, *14*, 637–643.
- (10) Colombo, G.; Clemente, N.; Zito, A.; Bracci, C.; Colombo, F. S.; Sangaletti, S.; Jachetti, E.; Ribaldone, D. G.; Caviglia, G. P.; Pastorelli, L.; De Andrea, M.; Naviglio, S.; Lucafò, M.; Stocco, G.; Grolla, A. A.; Campolo, M.; Casili, G.; Cuzzocrea, S.; Esposito, E.; Malavasi, F.; Genazzani, A. A.; Porta, C.; Travelli, C. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. *J. Mol. Med.* **2020**, *98*, 595–612.
- (11) Sun, D.; Zhang, J.; Dong, G.; He, S.; Sheng, C. Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation. *J. Med. Chem.* **2022**, *65*, 14276–14288.
- (12) Lin, C.; Yu, M.; Wu, X.; Wang, H.; Wei, M.; Zhang, L. Targeting moonlighting enzymes in cancer. *Molecules* **2024**, *29*, 1573.

- (13) Hinterdorfer, M.; Spiteri, V. A.; Ciulli, A.; Winter, G. E. Targeted protein degradation for cancer therapy. *Nat. Rev. Cancer* **2025**, *25*, 493–516.
- (14) Li, K.; Crews, C. M. PROTACs: past, present and future. *Chem. Soc. Rev.* **2022**, *51*, S214–S236.
- (15) Ding, Y.; Xing, D.; Fei, Y.; Lu, B. Emerging degrader technologies engaging lysosomal pathways. *Chem. Soc. Rev.* **2022**, *51*, 8832–8876.
- (16) Lu, T.; Chen, F.; Yao, J.; Bu, Z.; Kyani, A.; Liang, B.; Chen, S.; Zheng, Y.; Liang, H.; Neamati, N.; Liu, Y. Design of FK866-based degraders for blocking the nonenzymatic functions of Nicotinamide phosphoribosyltransferase. *J. Med. Chem.* **2024**, *67*, 8099–8121.
- (17) Wu, Y.; Pu, C.; Fu, Y.; Dong, G.; Huang, M.; Sheng, C. NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion. *Acta Pharm. Sin. B* **2022**, *12*, 2859–2868.
- (18) Bi, K.; Cheng, J.; He, S.; Fang, Y.; Huang, M.; Sheng, C.; Dong, G. Discovery of highly potent nicotinamide phosphoribosyltransferase degraders for efficient treatment of ovarian cancer. *J. Med. Chem.* **2023**, *66*, 1048–1062.
- (19) He, S.; Fang, Y.; Zhu, Y.; Ma, Z.; Dong, G.; Sheng, C. Drugamer-PROTAC conjugation strategy for targeted PROTAC delivery and synergistic antitumor therapy. *Adv. Sci.* **2024**, *11*, No. e2401623.
- (20) Cheng, J.; Zhang, J.; He, S.; Li, M.; Dong, G.; Sheng, C. Photoswitchable PROTACs for reversible and spatiotemporal regulation of NAMPT and NAD<sup>+</sup>. *Angew. Chem., Int. Ed.* **2024**, *63*, No. e202315997.
- (21) Dong, G.; Wu, Y.; Cheng, J.; Chen, L.; Liu, R.; Ding, Y.; Wu, S.; Ma, J.; Sheng, C. Ispinesib as an effective warhead for the design of Autophagosome-Tethering Chimeras: discovery of potent degraders of Nicotinamide phosphoribosyltransferase (NAMPT). *J. Med. Chem.* **2022**, *65*, 7619–7628.
- (22) Zhu, X.; Liu, H.; Chen, L.; Wu, C.; Liu, X.; Cang, Y.; Jiang, B.; Yang, X.; Fan, G. Addressing the enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation. *Cell Chem. Biol.* **2022**, *29*, 1616–1629.
- (23) Zhang, P.; Wang, W.; Guo, M.; Zhou, L.; Dong, G.; Xu, D.; Sheng, C. Discovery of potent NAMPT-targeting PROTACs using FK866 as the warhead. *Bioorg. Med. Chem. Lett.* **2023**, *92*, No. 129393.
- (24) Cheng, J.; He, S.; Xu, J.; Huang, M.; Dong, G.; Sheng, C. Making protein degradation visible: discovery of theranostic PROTACs for detecting and degrading NAMPT. *J. Med. Chem.* **2022**, *65*, 15725–15737.
- (25) Travelli, C.; Aprile, S.; Rahimian, R.; Grolla, A. A.; Rogati, F.; Bertolotti, M.; Malagnino, F.; Di Paola, R.; Impellizzeri, D.; Fusco, R.; Mercalli, V.; Massarotti, A.; Stortini, G.; Terrazzino, S.; Del Grosso, E.; Fakhfour, G.; Troiani, M. P.; Alisi, M. A.; Grosa, G.; Sorba, G.; Canonico, P. L.; Orsomando, G.; Cuzzocrea, S.; Genazzani, A. A.; Galli, U.; Tron, G. C. Identification of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors endowed with anti-proliferative and antiinflammatory activity. *J. Med. Chem.* **2017**, *60*, 1768–1792.
- (26) Tron, G. C.; Piralì, T.; Billington, R. A.; Canonico, P. L.; Sorba, G.; Genazzani, A. A. Click chemistry reactions in medicinal chemistry: applications of the 1,3-Dipolar cycloaddition between azides and alkynes. *Med. Res. Rev.* **2008**, *28*, 278–308.
- (27) Wurz, R. P.; Dellamaggiore, K.; Dou, H.; Javier, N.; Lo, M.-C.; McCarter, J. D.; Mohl, D.; Sastri, C.; Lipford, J. R.; Cee, V. J. A “Click Chemistry Platform” for the rapid synthesis of bispecific molecules for inducing protein degradation. *J. Med. Chem.* **2018**, *61*, 453–461.
- (28) Xia, L. W.; Ba, M. Y.; Liu, W.; Cheng, W.; Hu, C. P.; Zhao, Q.; Yao, Y. F.; Sun, M. R.; Duan, Y. T. Triazol: a privileged scaffold for proteolysis targeting chimeras. *Future Med. Chem.* **2019**, *11*, 2919–2973.
- (29) Ayinde, O. R.; Sharpe, C.; Stahl, E.; Tokarski, R. J., II; Lerma, J. R.; Muthusamy, N.; Byrd, J. C.; Fuchs, J. R. Examination of the impact of triazole position within linkers on solubility and lipophilicity of a CDK9 degrader series. *ACS Med. Chem. Lett.* **2023**, *14*, 936–942.
- (30) Bellenghi, M.; Talarico, G.; Botti, L.; Puglisi, R.; Tabolacci, C.; Portararo, P.; Piva, A.; Pontecorvi, G.; Carè, A.; Colombo, M. P.; Mattia, G.; Sangaletti, S. SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. *Oncogene* **2022**, *41*, 4055–4065.
- (31) Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A. M.; Wang, J.; Chen, X.; Dong, H.; Siu, K.; Winkler, J. D.; Crew, A. P.; Crews, C. M.; Coleman, K. G. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. *Proc. Natl. Acad. Sci. U.S.A.* **2016**, *113*, 7124–7129.
- (32) Marletta, A. S.; Massarotti, A.; Orsomando, G.; Magni, G.; Rizzì, M.; Garavaglia, S. Crystal structure of human nicotinic acid phosphoribosyltransferase. *FEBS Open Bio* **2015**, *5*, 419–428.
- (33) Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle, I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A. Structure-Guided Design and Optimization of Small Molecules Targeting the Protein-Protein Interaction between the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities. *J. Med. Chem.* **2014**, *57*, 8657–8663.
- (34) Ge, J.; Li, S.; Weng, G.; Wang, H.; Fang, M.; Sun, H.; Deng, Y.; Yu Hsieh, C.; Li, D.; Hou, T. PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters. *Nucleic Acids Res.* **2025**, *53*, D1510–D1515.
- (35) Teramoto, S.; Kaneda, M.; Aoyama, H.; Shirasu, Y. Correlation between the molecular structure of N-alkylureas and N-alkylthioureas and their teratogenic properties. *Teratology* **1981**, *23*, 335–342.
- (36) Wen, F.; Gui, G.; Wang, X.; Ye, L.; Qin, A.; Zhou, C.; Zha, X. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives. *Bioorg. Med. Chem.* **2024**, *99*, No. 117595.
- (37) Massarotti, A.; Aprile, S.; Mercalli, V.; Del Grosso, E.; Grosa, G.; Sorba, G.; Tron, G. C. Are 1,4- and 1,5-disubstituted 1,2,3-triazoles good pharmacophoric groups? *ChemMedChem* **2014**, *9*, 2497–2508.
- (38) Campone, M.; De Laurentis, M.; Jhaveri, K.; Hu, X.; Ladoire, S.; Patsouris, A.; Zamagni, C.; Cui, J.; Cazzaniga, M.; Cil, T.; Jerzak, K. J.; Fuentes, C.; Yoshinami, T.; Rodriguez-Lescure, A.; Sezer, A.; Fontana, A.; Guarneri, V.; Molckovsky, A.; Mouret-Reynier, M.-A.; Demirci, U.; Zhang, Y.; Valota, O.; Lu, D. R.; Martignoni, M.; Parameswaran, J.; Zhi, X.; Hamilton, E. P. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. *N. Engl. J. Med.* **2025**, *393*, 556.
- (39) He, S.; Gao, F.; Ma, J.; Ma, H.; Dong, G.; Sheng, C. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. *Angew. Chem., Int. Ed.* **2021**, *60*, 23299–23305.
- (40) Grolla, A. A.; Torretta, S.; Gnemmi, I.; Amoruso, A.; Orsomando, G.; Gatti, M.; Caldarelli, A.; Lim, D.; Penengo, L.; Brunelleschi, S.; Genazzani, A. A.; Travelli, C. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma. *Pigm. Cell Melanoma Res.* **2015**, *28*, 718–729.
- (41) Orsomando, G.; Cialabrini, L.; Amici, A.; Mazzola, F.; Ruggieri, S.; Conforti, L.; Janeckova, L.; Coleman, M. P.; Magni, G. Simultaneous single-sample determination of NMNAT isozyme activities in mouse tissues. *PLoS One* **2012**, *7*, No. e53271.
- (42) Amici, A.; Grolla, A. A.; Del Grosso, E.; Bellini, R.; Bianchi, M.; Travelli, C.; Garavaglia, S.; Sorci, L.; Raffaelli, N.; Ruggieri, S.; Genazzani, A. A.; Orsomando, G. Synthesis and Degradation of Adenosine 5'-Tetraphosphate by Nicotinamide and Nicotinate Phosphoribosyltransferases. *Cell Chem. Biol.* **2017**, *24*, 553–564.e4.
- (43) Mori, V.; Amici, A.; Mazzola, F.; Di Stefano, M.; Conforti, L.; Magni, G.; Ruggieri, S.; Raffaelli, N.; Orsomando, G. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. *PLoS One* **2014**, *9*, No. e113939.
- (44) Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. *Comput. Methods Progr. Biomed.* **2010**, *99*, 306–314.
- (45) OMEGA 4.1.0.2: OpenEye Scientific Software, Santa Fe, NM, USA. <http://www.eyesopen.com>.
- (46) Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database. *J. Chem. Inf. Model.* **2010**, *50*, 572–584.

- (47) FRED 4.0.0.2: OpenEye Scientific Software, Santa Fe, NM. <http://www.eyesopen.com>.
- (48) McGann, M. FRED Pose Prediction and Virtual Screening Accuracy. *J. Chem. Inf. Model.* **2011**, *51*, 578–596.
- (49) McGann, M. FRED and HYBRID docking performance on standardized datasets. *J. Comput. Aided Mol. Des.* **2012**, *26*, 897–906.
- (50) Garzon, J. I.; López-Blanco, J. R.; Pons, C.; Kovacs, J.; Abagyan, R.; Fernandez-Recio, J.; Chacon, P. FRODOCK: a new approach for fast rotational protein–protein docking. *Bioinformatics* **2009**, *25*, 2544–2551.
- (51) Gray, J. J.; Moughon, S.; Wang, C.; Schueler -Furman, O.; Kuhlman, B.; Rohl, C. A.; Baker, D. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. *J. Mol. Biol.* **2003**, *331*, 281–299.
- (52) RDKit: Open-source cheminformatics. <https://www.rdkit.org>.
- (53) Schrödinger Release 2025–1: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2024. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2025.



CAS BIOFINDER DISCOVERY PLATFORM™

## CAS BIOFINDER HELPS YOU FIND YOUR NEXT BREAKTHROUGH FASTER

Navigate pathways, targets, and  
diseases with precision

Explore CAS BioFinder

